

JC542 U.S. PTO
11/24/98

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. **JB0800**First Inventor or Application Identifier **Malcolm et al.**Title **Covalent Complexes of HCV NS3 Protease**Express Mail Label No. **EL226882780US**J-203/98728
J-24/98**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1. * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification [Total Pages **59**] (preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) [Total Sheets **7**]
4. Oath or Declaration [Total Pages]
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 C.F.R. § 1.63(d)) (for continuation/divisional with Box 16 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

*NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. Computer Readable Copy
 - b. Paper Copy (identical to computer copy)
 - c. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. Assignment Papers (cover sheet & document(s))
8. 37 C.F.R. §3.73(b) Statement Power of (when there is an assignee) Attorney
9. English Translation Document (if applicable)
10. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
11. Preliminary Amendment
12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
13. * Small Entity Statement(s) Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired
14. Certified Copy of Priority Document(s) (if foreign priority is claimed)
15. Other:

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:


 Continuation Divisional Continuation-in-part (CIP) of prior application No: _____ / _____

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label		(Insert Customer No. or Attach bar code label here)			or <input type="checkbox"/> Correspondence address below
Name	Jaye P. McLaughlin				
	Schering-Plough Corporation				
Address	2000 Galloping Hill Road				
	Kenilworth		State	New Jersey	
City	Kenilworth		State	New Jersey	07033
Country	USA		Telephone	(908) 298-5056	Fax
					(908) 298-5388

Name (Print/Type)	Jaye P. McLaughlin	Registration No. (Attorney/Agent)	41,211
Signature			Date 11/24/98

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**SINGLE-CHAIN RECOMBINANT COMPLEXES OF HEPATITIS C
VIRUS NS3 PROTEASE AND NS4A COFACTOR PEPTIDE**

5

This filing is a conversion of Provisional U.S. Patent Applications USSN 60/067,315, filed November 28, 1997 and USSN 60/094,331, filed July 28, 1998, each of which is incorporated herein by reference, to a U.S. Utility Patent Application.

10

BACKGROUND OF THE INVENTION

Hepatitis C virus (HCV) is considered to be the major etiological agent of non-A non-B (NANB) hepatitis, chronic liver disease, and hepatocellular carcinoma (HCC) around the world, with an estimated human seroprevalence of 1% globally. [Alter *et al.*, 1994, *Gastroenterol. Clin. North Am.* 23:437-455; Behrens *et al.*, 1996, *EMBO J.* 15:12-22]. Four million individuals may be infected in the United States. The viral infection accounts for greater than 90% of transfusion-associated hepatitis in the U.S. and it is the predominant form of hepatitis in adults over 40 years of age. Almost all of the infections result in chronic hepatitis and nearly 20% of those infected develop liver cirrhosis.

The virus particle has not been identified due to the lack of an efficient *ex vivo* replication system and the extremely low amount of HCV particles in infected liver tissues or blood. However, molecular cloning of the viral genome has been accomplished by isolating the messenger RNA (mRNA) from the serum of infected chimpanzees and preparing cDNA using recombinant methodologies. [Grakoui A. *et al.*, 1993, *J. Virol.* 67: 1385-1395]. It is now known that HCV contains a positive strand RNA genome comprising approximately 9400 nucleotides, organization of which is similar to that of flaviviruses and pestiviruses. The genome of HCV, a (+)-stranded RNA molecule of ~9.4 kb, encodes a single large polyprotein of about 3000 amino acids which undergoes proteolysis to form mature viral proteins in infected cells.

Cell-free translation of the viral polyprotein and cell culture expression studies have established that the HCV polyprotein is

processed by cellular and viral proteases to produce the putative structural and nonstructural (NS) proteins. At least ten mature viral proteins are produced from the polyprotein by specific proteolysis. The order and nomenclature of the cleavage products are as follows: NH₂-C-
5 E1-E2-p7-NS2-NS4A-NS3-NS4B-NS5A-NS5B-COOH (Fig. 1) [Grakoui *et al.*, 1993, *J. Virol.* 67:1385-95; Hijikata *et al.*, 1991, *PNAS* 88:5547-51; Lin *et al.*, 1994, *J. Virol.* 68:5063-73]. The three amino-terminal putative structural proteins, C (capsid), E1, and E2 (two envelope glycoproteins), are believed to be cleaved by a host signal peptidase of the endoplasmic
10 reticulum (ER). The host enzyme is also responsible for generating the amino terminus of NS2. The proteolytic processing of the nonstructural proteins are carried out by the viral proteases: NS2-3 and NS3, contained within the viral polyprotein. The NS2-3 protease catalyzes the cleavage between NS2 and NS3. It is a metalloprotease and requires both NS2 and
15 the protease domain of NS3.

The NS3 protease catalyzes the rest of the cleavages in the nonstructural part of the polyprotein. The NS3 protein contains 631 amino acid residues and is comprised of two enzymatic activities: the
20 protease domain contained within amino acid residues 1-181 and a helicase ATPase domain contained within the rest of the protein Kim *et al.*, 1995, *Biochem Biophys Res. Comm.*, 215:160-166. It is not known if the 70 kD NS3 protein is cleaved further in infected cells to separate the protease domain from the helicase domain, although no cleavage has
25 been observed in cell culture expression studies.

The NS3 protease is a member of the serine class of enzymes. It uses a His, Asp, Ser catalytic triad. Mutation of the Ser residue abolishes cleavage of NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B substrates. The
30 cleavage between NS3 and NS4A is intramolecular, whereas the cleavages at the NS 4A/4B, 4B/5A, 5A/5B sites occur in *trans*.

Experiments using transient expression of various forms of HCV NS polyproteins in mammalian cells have established that the NS3 serine protease is necessary but not sufficient for efficient processing of all of these cleavages. Like the flaviviruses, the HCV NS3 protease also requires a cofactor to catalyze some of these cleavage reactions. Efficient proteolytic processing at NS3/4A, NS4A/4B, NS4B/5A, and NS5A/5B

sites within the non-structural domain of hepatitis C virus requires a heterodimeric complex of the NS3 serine protease and the NS4A protein. [Bartenschlager *et al.* 1995, *J. Virol.* **67**:3835-3844; Failla *et al.*, 1994, *J. Virol.* **68**:3753-3760]. A 13-amino acid synthetic NS4A peptide,
5 corresponding to the central hydrophobic domain of NS4A protein, spanning residues 21-33 has been shown to be sufficient for activation of NS3 protease [Butkiewicz *et al.*, 1996, *Virology*, **225**: 328-338]. A smaller domain (amino acid residues 22-30) of NS4A has been shown to be sufficient for activation of the protease [Lin *et al.*, 1995, *J. Virol.* **69**:4377-
10 80].

The recently published three dimensional structure of the NS3 protease [Kim *et al.*, 1996, *Cell* **87**:343-355; Love *et al.*, 1996, *Cell* **87**:331-342] revealed that the N-terminal 37 residues of NS3 adopt a β (residues 6-9)-
15 α (residues 14-22)- β (residues 33-37) structure upon binding of a synthetic peptide corresponding to the central hydrophobic domain spanning residues 21-32 of NS4A protein.

Production of an active NS3₁₋₁₈₁-NS4A peptide complex at
20 present involves two steps. First, the NS3 catalytic domain (amino acid residues 1-181) is produced as a recombinant protein in *E. coli*. Next, a 13-19 residue NS4A peptide spanning the central hydrophobic domain of the full-length NS4A protein is added to form a non-covalent complex [Kim *et al.*, 1996, *Cell* **87**:343-355]. This complex, although more active
25 than the protease alone, is approximately 8-10 fold less active than the full-length NS3₁₋₆₃₁-NS4A₁₋₅₄ form of the protease as judged by its proteolytic activity toward a synthetic substrate based on the native NS5A-NS5B amino acid sequence. [Urbani *et al.*, 1997, *J. Biol. Chem.*, **272**(14):9204-09; Steinkuhler *et al.*, 1996, *J. Virol.* **70**(10):6694-6700].
30 Moreover, NS4A peptide has been shown to have a very low affinity (10 μ M) for NS3 in solution [Bianchi *et al.*, 1997, *Biochemistry* **36**: 7890-7897], requiring addition of NS4A peptide in the high micromolar range to insure a 1:1 stoichiometric complex with NS3 protease. The limited solubility of this peptide in aqueous buffer due to its hydrophobic nature
35 makes working with this peptide at these concentrations difficult.

Because the HCV NS3 protease cleaves the non-structural HCV proteins necessary for HCV replication, the NS3 protease can be a target

for the development of therapeutic agents against the HCV virus. The gene encoding the HCV NS3 protein has been cloned as disclosed in U.S. Patent No. 5,371,017. To date, however, the protease has not been produced in a covalent complex with the NS4A cofactor in a soluble, 5 active and stable form. Such a complex would be useful as a target in a high throughput screen to discover therapeutic agents. A stable, active HCV protease is also required for determination of modes of binding of inhibitors by NMR, for structural determination by NMR spectroscopy, for crystallography, and for virtually all biophysical and biochemical 10 studies interested in the activated form of the enzyme.

SUMMARY OF THE INVENTION

15 The present invention provides NS4A tethered forms of the HCV NS3 protease comprising single-chain recombinant covalent complexes of Hepatitis C virus NS3 protease and an NS4A cofactor peptide which require no subsequent addition of NS4A peptide for activation and which are as active as the full-length NS3₁₋₆₃₁ NS4A₁₋₅₄. The covalent 20 NS4A-NS3 complexes of the invention are more soluble, stable and active than the non-covalent protease-peptide complexes previously available.

25 The NS4A tethered forms of the HCV NS3 protease of the invention consist of covalent NS4A-NS3 complexes comprising a central hydrophobic domain of the NS4A peptide tethered by linker of at least about 4 amino acid residues to the amino terminus of the serine protease domain of NS3. The amino acid sequences of 20 such embodiments are defined in the Sequence Listing by SEQ ID NOs: 1-20. 30 Corresponding nucleotide sequences are provided in SEQ ID NOs: 91-111.

Preferred embodiments of the invention also provide NS4A tethered forms of the full length NS3 protease. The amino acid 35 sequences of 8 such embodiments are defined in SEQ ID NOs: 11-18.

Other preferred embodiments of the invention further provide mutant forms of the covalent NS4A-NS3 complexes in which point

mutations introduced at positions 17 and/or 18 of the NS3 domain change a hydrophobic amino acid residue to a hydrophilic residue. This further improves the solubility of the complexes and provides the protein in a monodispersed form. The amino acid sequences of 13 such 5 embodiments are defined in the Sequence Listing by SEQ ID NOS: 2-4, 6-8, 10, 12-14, and 16-18.

The invention still further provides mutant forms of the covalent NS4A-NS3 complexes in which a mutation introduced at position 139 of 10 the NS3 domain changes a serine residue to an alanine residue. The amino acid sequences of 9 such embodiments are defined in SEQ ID NOS: 5-8, 15-18 and 20.

The invention further provides covalent HCV NS4A-NS3 15 complexes having an easily removable histidine tag comprising three or more histidine residues fused to the complex. This enables rapid purification of the protease with easy removal of the tag following purification.

20 The present invention further provides for isolated nucleic acids and vectors which encode the covalent NS4A-NS3 complexes of the present invention, and host cells transformed or transfected by said nucleic acids or vectors.

25 The invention still further provides methods for making the covalent NS4A-NS3 complexes comprising culturing the transformed or transfected host cell under conditions in which the nucleic acid or vector is expressed.

30 The invention also provides methods for identifying inhibitors of HCV NS3. Methods are provided for detecting inhibitors of the protease activity, the helicase activity and the ATPase activity of NS3 using the disclosed covalent complexes.

35

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 schematically depicts the HCV genome.

Figure 2 depicts the recombinant synthesis of plasmid pHIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁.

- 5 Figure 3 depicts the recombinant synthesis of plasmid pHIS-NS3₁₋₆₃₁.

Figure 4 depicts the recombinant synthesis of plasmid pHIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁.

10

Figures 5A and 5B schematically depict a high throughput assay for discovering HCV protease inhibitors using surface plasmon resonance technology. Figure 5A illustrates the outcome expected in the absence of an uninhibited HCV protease, while 5B illustrates the outcome expected in the presence of an active, uninhibited HCV protease.

15

Figure 6 shows the nucleic acid unwinding activity of the covalent His-NS4A₂₁₋₃₂-GSGS-NS₃₃₋₆₃₁ as compared to that of the His NS3₁₋₆₃₁/NS4A₁₋₅₄

20

Figure 7 shows the ATPase activity of the covalent His-NS4A₂₁₋₃₂-GSGS-NS₃₃₋₆₃₁ complex as monitored by thin layer chromatography.

DETAILED DESCRIPTION OF THE INVENTION

25

The teachings of all references cited are incorporated herein in their entirety by reference.

30

The covalent NS4A-NS3 complexes of the present invention are useful for structural determination and determination of mode of binding of HCV inhibitors by NMR spectroscopy. Moreover, they provide a more soluble and stable form of HCV NS3 protease than the presently available non-covalent NS3₁₋₁₈₁-NS4A peptide complexes for crystallography studies, high throughput screening assays and other conventional biophysical and biochemical investigations.

35 Several representative embodiments of the covalent NS4A-NS3 complexes of the invention are disclosed in the examples below. In one

such embodiment, NS4A residues 21-32 were tethered to the amino terminus of residues 3-181 of mature NS3 protease by a 4-residue linker, GSGS (SEQ ID NO: 21). The complex was overexpressed as a soluble protein in *E. coli* and purified to homogeneity by a combination of metal chelate and size-exclusion chromatography. The tethered complex, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ (SEQ ID NO: 1) cleaved a NS5A/5B synthetic substrate with a catalytic efficiency identical to that of the non-covalent full-length protease, NS3₁₋₆₃₁-NS4A₁₋₅₄.

In other embodiments of the invention, the NS4A hydrophobic domain and the NS3 serine protease domain are covalently tethered using different amino acid linkers. The preferred amino acid linkers of the invention comprise at least about four amino acid residues. More preferably, the linkers consist of from four to six amino acid residues.

More preferably, four-residue linkers are used. Most preferably, amino acid linkers having the sequence defined by SEQ ID NO: 21 or 22 are used to tether the NS4A hydrophobic domain and the NS3 serine protease domain.

Routine procedures in the art would allow one to construct covalent NS4A-NS3 complexes of the invention having linkers of various sizes. It will be understood by one skilled in the art, for example, that if smaller or larger portions of the NS3 or NS4A domains are used to construct the covalent complexes of the invention, longer or shorter amino acid linkers can be used.

Other embodiments of the present invention contain smaller or larger portions of the NS4A cofactor peptide. In preferred embodiments, the complexes contain an NS4A hydrophobic domain comprising at least amino acid residues 22-30 of the full length NS4A cofactor peptide. More preferably, the complexes contain from 12-19 amino acid residues spanning the central hydrophobic domain of the full length NS4A peptide. Most preferably, the complexes contain amino acid residues 21-32 of full length NS4A peptide.

Still further embodiments of the present invention contain smaller or larger portions of the NS3 protease. In preferred embodiments, the complexes contain an NS3 serine protease domain

comprising at least amino acid residues 3-181 of the full length NS3 protease. More preferably, the complexes contain amino acid residues 1-181 of full length NS3 protease. Most preferably, the complexes contain amino acid residues 3-181 of full length NS3 protease.

5

The present invention thus also includes covalent NS4A-NS3 complexes comprising the central hydrophobic domain of the NS4A peptide tethered to the amino terminus of full-length mature NS3 protease (amino acids 1-631) by an amino acid linker. The amino acid sequences of preferred embodiments comprising NS4A tethered to full-length mature NS3 protease are set forth in SEQ ID NOs: 11-18.

Surprisingly, it has also been found that the introduction of point mutations at position 17 and/or 18 of the NS3 domain of the NS4A- NS3 constructs of the present invention which change a hydrophobic amino acid residue to a hydrophilic amino acid residue produces a more soluble and mono-dispersed form of the tethered complex. Thirteen representative embodiments of such mutant NS4A-NS3 complexes are disclosed in the Examples below. In some embodiments, the isoleucine at position 17 is mutated to lysine. One such mutant form is referred to as His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I17K (SEQ ID NO: 2). In other embodiments, the same mutation is made at position 18. One such mutant form is referred to as His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K (SEQ ID NO: 3). In yet other embodiments, the mutations are introduced at both positions. One such mutant is referred to as His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I17K,I18K (SEQ ID NO: 4). Each of the purified mutants results in a monodispersed (as judged by size exclusion chromatography) and more soluble (as judged by achieving higher concentration of the complex 17-20 mg/ml) form of the complex, which remains monodispersed for a period of about one week at 4°C, while still exhibiting kinetic properties identical to those of the wild type.

It will be understood that although the foregoing embodiments are presently preferred, other modifications to the hydrophobic residues at positions 17 and 18 can be made to produce other soluble complexes. Preferably, neutral amino acid residues will be substituted for charged residues. These modifications can be used in a number of combinations to produce the final modified protein chain.

Also provided are NS4A-tethered forms of NS3 full-length domain. In contrast to the NS4A-tethered forms of the catalytic domain, a considerable amount of autocleavage in the helicase domain of the
5 NS3 protein is detected during the purification of their native full-length counterpart, HIS-NS4A₂₁₋₃₂-NS3₃₋₆₃₁. To prevent autocleavage of the full-length covalent complexes, the catalytic serine residue at position 139 is mutated to alanine. The amino acid sequence of one such embodiment is defined by SEQ ID NO: 15. The mutation of the full
10 length constructs at position 139 can also be made in the NS4A-tethered forms of the NS3 catalytic domain, and can be made in combination with any of the aforementioned mutations to increase solubility and stability while preventing autocleavage. Representative embodiments are set forth in SEQ ID NOs: 5-8, 15-18 and 20.

15

As used herein, the terms "native NS3" and "full-length NS3" are used interchangeably and are defined as a protein which (a) has an amino acid sequence substantially identical to the sequence defined by SEQ ID NO: 23 and (b) has biological activity that is common to native
20 NS3. This includes natural allelic variants and other variants having one or more conservative amino acid substitutions [Grantham, 1974, *Science* 185:862] that do not substantially impair biological activity. Such conservative substitutions involve groups of synonymous amino acids, e.g., as described in U.S. patent No. 5,017,691 to Lee *et al.*

25

The "serine protease domain" of NS3 or the "catalytic domain" of NS3 refers to amino acids 1-181 of mature NS3, which have been shown to contain the active catalytic triad His, Asp and Ser.

30

The term "native NS4A peptide" as used herein is defined as a peptide which (a) has an amino acid sequence substantially identical to the sequence defined by SEQ ID NO: 24; and (b) has biological activity that is common to native NS4A. This includes natural allelic variants and other variants having one or more conservative amino acid substitution [Grantham, 1974, *Science* 185:862] that do not substantially impair biological activity. Such conservative substitutions involve groups of synonymous amino acids, e.g., as described in U.S. patent No. 5,017,691 to Lee *et al.*

35

USPTO TRANSFER OF RECORD

As used herein, the "central hydrophobic domain of NS4A peptide" refers to that portion of the native NS4A peptide (approximately amino acid residues 22 - 30) which is sufficient for activation of NS3 protease. Size and sequence variants of this domain which also activate the NS3 protease in the claimed complexes also fall within this term.

A "soluble" covalent complex as referred to herein is defined as a protein which will remain in solution after a high spin centrifugation step at 300,000 x g in a standard ultracentrifuge in a buffer containing 25 mM HEPES, pH 7.6, 10% glycerol, 0.3 M NaCl, 10 mM β ME.

An "active" covalent complex as referred to herein is defined as a complex which will cleave synthetic substrates corresponding to NS5A-NS5B cleavage site (for example, DTEDVVCC SMYTWTGK) (SEQ ID NO: 25)) between P1 residue, cysteine and P1' residue, serine in a buffer containing 25 mM Tris, pH 7.5, 150 mM NaCl, 10 % glycerol, and 0.05 % lauryl maltoside.

20

Nucleic acids encoding the covalent NS4A-NS3 complexes are also a part of this invention. DNA encoding the covalent NS4A-NS3 complexes of this invention can be prepared by chemical synthesis using the known nucleic acid sequence [Ratner *et al.*, 1985, *Nucleic Acids Res.* 13:5007] and standard methods such as the phosphoramidite solid support method of Matteucci *et al.*, 1981, *J. Am. Chem. Soc.* 103:3185 or the method of Yoo *et al.*, 1989, *J. Biol. Chem.* 264:17078. See also Glick, Bernard R. and Pasternak, *Molecular Biotechnology*, pages 55 - 63, (ASM Press, Washington, D.C. 1994).
25 The genes encoding the desired regions of the HCV protein can also be obtained using the plasmid disclosed in Grakoui, *et al.*, 1993, *J. Virol.* 67:1385-1395 or that disclosed in Takamizawa *et al.*, 1991, *J. Virology* 65(3):1105-1113. Also, the nucleic acid encoding HCV NS3 and NS4A can be isolated, amplified and cloned from patients infected with the HCV virus. Furthermore, the HCV genome has
30 been disclosed in PCT WO 89/04669 and is available from the
35

American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD under ATCC accession no. 40394.

Of course, because of the degeneracy of the genetic code, there are many functionally equivalent nucleic acid sequences that can encode the NS3 and NS4A domains of the covalent NS4A-NS3 complexes as defined herein. Such functionally equivalent sequences, which can readily be prepared using known methods such as chemical synthesis, PCR employing modified primers and site-directed mutagenesis, are within the scope of this invention.

10

Various vectors can be used to express DNA encoding the covalent NS4A-NS3 complexes. Conventional vectors used for expression of recombinant proteins in prokaryotic or eukaryotic cells may be used. Preferred vectors include the pET vectors described by Studier *et al.*, 1990, *Methods of Enzymology* 185: 60-89, and the pcD vectors described by Okayama *et al.*, 1983, *Mol. Cell. Bio.* 3: 280-289; and Takebe *et al.*, 1988, *Mol. Cell. Biol.* 8: 466-472. Other SV40-based mammalian expression vectors include those disclosed in Kaufman *et al.*, 1982, *Mol. Cell. Biol.* 2: 1304-1319 and U.S. Patent No. 4,675,285. These SV40-based vectors are particularly useful in COS7 monkey cells (ATCC No. CRL 1651), as well as in other mammalian cells such as mouse L cells and CHO cells.

Standard transfection methods can be used to produce eukaryotic cell lines which express large quantities of polypeptides. Eukaryotic cell lines include mammalian, yeast and insect cell lines. Exemplary mammalian cell lines include COS-7 cells, mouse L cells and Chinese Hamster Ovary (CHO) cells. See Sambrook *et al.*, *supra* and Ausubel *et al.*, *supra*.

30

As used herein, the term "transformed bacteria" means bacteria that have been genetically engineered to produce a viral or mammalian protein. Such genetic engineering usually entails the introduction of an expression vector into a bacterium. The expression vector is capable of autonomous replication and protein expression relative to genes in the bacterial genome. Construction of bacterial expression vectors is well known in the art, provided the nucleotide sequence encoding a desired

protein is known or otherwise ascertainable. For example, DeBoer in U.S. Pat. No. 4,551,433 discloses promoters for use in bacterial expression vectors; Goeddel *et al.* in U.S. Pat. No. 4,601,980 and Riggs, in U.S. Pat. No. 4,431,739 disclose the production of mammalian proteins by *E. coli* expression systems; and Riggs *supra*, Ferretti *et al.*, 1986, *Proc. Natl. Acad. Sci.* 83:599, Sproat *et al.*, 1985, *Nucleic Acid Research* 13:2959 and Mullenbach *et al.*, 1986, *J. Biol. Chem.* 261:719 disclose how to construct synthetic genes for expression in bacteria. Many bacterial expression vectors are available commercially and through the American Type Culture Collection (ATCC), Rockville, Maryland.

Insertion of DNA encoding the covalent NS4A-NS3 complexes into a vector is easily accomplished when the termini of both the DNA and the vector comprise the same restriction site. If this is not the case, it may be necessary to modify the termini of the DNA and/or vector by digesting back single-stranded DNA overhangs generated by restriction endonuclease cleavage to produce blunt ends, or to achieve the same result by filling in the single-stranded termini with an appropriate DNA polymerase.

Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the termini. Such linkers may comprise specific oligonucleotide sequences that define desired restriction sites. The cleaved vector and the DNA fragments may also be modified if required by homopolymeric tailing.

Many *E. coli*-compatible expression vectors can be used to produce soluble covalent NS4A-NS3 complexes of the present invention, including but not limited to vectors containing bacterial or bacteriophage promoters such as the *Tac*, *Lac*, *Trp*, *LacUV5*, λ *P_r* and λ *P_L* promoters. Preferably, a vector selected will have expression control sequences that permit regulation of the rate of expression. Then, production of covalent NS4A-NS3 complexes can be regulated to avoid overproduction that could prove toxic to the host cells. Most preferred is a vector comprising, from 5' to 3' (upstream to downstream), a *Tac* promoter, a *lac I^Q* repressor gene and DNA encoding mature human HCV protease. The vectors chosen for use in this invention may also encode secretory leaders such as the *ompA* or protein A leader, as long as such leaders are cleaved during

post-translational processing to produce covalent NS4A-NS3 complexes or if the leaders are not cleaved, the leaders do not interfere with the enzymatic activity of the protease.

5 The covalent complexes of the invention, or portions thereof, can also be synthesized by a suitable method such as by exclusive solid phase synthesis, partial solid phase methods, fragment condensation or classical solution synthesis. The polypeptides are preferably prepared by solid phase peptide synthesis as described by Merrifield, 1963, *J. Am. Chem. Soc.* 85:2149. The synthesis is carried out with amino acids that are protected at the alpha-amino terminus. Trifunctional amino acids with labile side-chains are also protected with suitable groups to prevent undesired chemical reactions from occurring during the assembly of the polypeptides. The alpha-amino protecting group is selectively removed 10 to allow subsequent reaction to take place at the amino-terminus. The conditions for the removal of the alpha-amino protecting group do not remove the side-chain protecting groups.

15

20 The alpha-amino protecting groups are those known to be useful in the art of stepwise polypeptide synthesis. Included are acyl type protecting groups (e.g., formyl, trifluoroacetyl, acetyl), aryl type protecting groups (e.g., biotinyl), aromatic urethane type protecting groups [e.g., benzyloxycarbonyl (Cbz), substituted benzyloxycarbonyl and 9-fluorenylmethoxy-carbonyl (Fmoc)], aliphatic urethane 25 protecting groups [e.g., t-butyloxycarbonyl (tBoc), isopropylloxycarbonyl, cyclohexyloxycarbonyl] and alkyl type protecting groups (e.g., benzyl, triphenylmethyl). The preferred protecting groups are tBoc and Fmoc, thus the peptides are said to be synthesized by tBoc and Fmoc chemistry, respectively.

30

35 The side-chain protecting groups selected must remain intact during coupling and not be removed during the deprotection of the amino-terminus protecting group or during coupling conditions. The side-chain protecting groups must also be removable upon the completion of synthesis, using reaction conditions that will not alter the finished polypeptide. In tBoc chemistry, the side-chain protecting groups for trifunctional amino acids are mostly benzyl based. In Fmoc chemistry, they are mostly tert.-butyl or trityl based.

In tBoc chemistry, the preferred side-chain protecting groups are tosyl for Arg, cyclohexyl for Asp, 4-methylbenzyl (and acetamidomethyl) for Cys, benzyl for Glu, Ser and Thr, 5 benzyloxymethyl (and dinitrophenyl) for His, 2-Cl-benzyloxycarbonyl for Lys, formyl for Trp and 2-bromobenzyl for Tyr. In Fmoc chemistry, the preferred side-chain protecting groups are 2,2,5,7,8-pentamethylchroman-6-sulfonyl (Pmc) or 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, trityl for 10 Asn, Cys, Gln and His, tert butyl for Asp, Glu, Ser, Thr and Tyr, tBoc for Lys and Trp.

For the synthesis of phosphopeptides, either direct or post-assembly incorporation of the phosphate group is used. In the direct 15 incorporation strategy, the phosphate group on Ser, Thr or Tyr may be protected by methyl, benzyl or tert.butyl in Fmoc chemistry or by methyl, benzyl or phenyl in tBoc chemistry. Direct incorporation of phosphotyrosine without phosphate protection can also be used in Fmoc chemistry. In the post-assembly incorporation strategy, the 20 unprotected hydroxyl group of Ser, Thr or Tyr is derivatized on solid phase with di-tert.butyl-, dibenzyl- or dimethyl-N,N'-diisopropylphosphoramidite and then oxidized by tert.butylhydroperoxide.

Solid phase synthesis is usually carried out from the carboxyl-terminus by coupling the alpha-amino protected (side-chain 25 protected) amino acid to a suitable solid support. An ester linkage is formed when the attachment is made to a chloromethyl, chlorotriyl or hydroxymethyl resin, and the resulting polypeptide will have a free carboxyl group at the C-terminus. Alternatively, when an amide 30 resin such as benzhydrylamine or *p*-methylbenzhydrylamine resin (for tBoc chemistry) and Rink amide or PAL resin (for Fmoc chemistry) is used, an amide bond is formed and the resulting polypeptide will have a carboxamide group at the C-terminus. These 35 resins, whether polystyrene- or polyamide-based or polyethyleneglycol-grafted, with or without a handle or linker, with or without the first amino acid attached, are commercially available, and their preparations have been described by Stewart et al (1984).,

"Solid Phase Peptide Synthesis" (2nd Edition), Pierce Chemical Co., Rockford, IL.; and Bayer & Rapp (1986) Chem. Pept. Prot. 3, 3; and Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford.

5

The C-terminal amino acid, protected at the side-chain if necessary and at the alpha-amino group, is attached to a hydroxymethyl resin using various activating agents including dicyclohexylcarbodiimide (DCC), N,N'-diisopropylcarbodiimide (DIPCDI) and carbonyldiimidazole (CDI). It can be attached to chloromethyl or chlorotriyl resin directly in its cesium tetramethylammonium salt form or in the presence of triethylamine (TEA) or diisopropylethylamine (DIEA). First amino acid attachment to an amide resin is the same as amide bond formation during coupling reactions.

10

15

Following the attachment to the resin support, the alpha-amino protecting group is removed using various reagents depending on the protecting chemistry (e.g., tBoc, Fmoc). The extent of Fmoc removal can be monitored at 300-320 nm or by a conductivity cell. After removal of the alpha-amino protecting group, the remaining protected amino acids are coupled stepwise in the required order to obtain the desired sequence.

20

25

Various activating agents can be used for the coupling reactions including DCC, DIPCDI, 2-chloro-1,3-dimethylimidium hexafluorophosphate (CIP), benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) and its pyrrolidine analog (PyBOP), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP), O -(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and its tetrafluoroborate analog (TBTU) or its pyrrolidine analog (HBPyU), O -(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) and its tetrafluoroborate analog (TATU) or pyrrolidine analog (HAPyU). The most common catalytic additives used in coupling reactions include 4-dimethylaminopyridine (DMAP), 3-hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HODhb), N-hydroxybenzotriazole (HOBt) and 1-

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

hydroxy-7-azabenzotriazole (HOAt). Each protected amino acid is used in excess (>2.0 equivalents), and the couplings are usually carried out in N-methylpyrrolidone (NMP) or in DMF, CH₂Cl₂ or mixtures thereof. The extent of completion of the coupling reaction
5 can be monitored at each stage, e.g., by the ninhydrin reaction as described by Kaiser et al., Anal. Biochem. 34:595 (1970). In cases where incomplete coupling is found, the coupling reaction is extended and repeated and may have chaotropic salts added. The coupling reactions can be performed automatically with commercially
10 available instruments such as ABI model 430A, 431A and 433A peptide synthesizers.

After the entire assembly of the desired polypeptide, the polypeptide-resin is cleaved with a reagent with proper scavengers.
15 The Fmoc peptides are usually cleaved and deprotected by TFA with scavengers (e.g., H₂O, ethanedithiol, phenol and thioanisole). The tBoc peptides are usually cleaved and deprotected with liquid HF for 1-2 hours at -5 to 0°C, which cleaves the polypeptide from the resin and removes most of the side-chain protecting groups. Scavengers
20 such as anisole, dimethylsulfide and p-thiocresol are usually used with the liquid HF to prevent cations formed during the cleavage from alkylating and acylating the amino acid residues present in the polypeptide. The formyl group of Trp and dinitrophenyl group of His need to be removed, respectively, by piperidine and thiophenol in
25 DMF prior to the HF cleavage. The acetamidomethyl group of Cys can be removed by mercury(II) acetate and alternatively by iodine, thallium (III) trifluoroacetate or silver tetrafluoroborate which simultaneously oxidize cysteine to cystine. Other strong acids used for tBoc peptide cleavage and deprotection include
30 trifluoromethanesulfonic acid (TFMSA) and trimethylsilyltrifluoroacetate (TMSOTf).

Recombinant DNA methodology can also be used to prepare the polypeptides. The known genetic code, tailored if desired with
35 known preferred codons for more efficient expression in a given host organism, can be used to synthesize oligonucleotides encoding the desired amino acid sequences. The phosphoramidite solid support method of Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981) or other

known methods can be used for such syntheses. The resulting oligonucleotides can be inserted into an appropriate vector and expressed in a compatible host organism.

- 5 The polypeptides of the invention can be purified using HPLC, gel filtration, ion exchange and partition chromatography, countercurrent distribution or other well known methods. In a preferred embodiment of the present invention the covalent NS4A-NS3 complexes also contain a histidine tag which facilitates purification using a Ni⁺ column as is
10 illustrated below.

- One can use the covalent NS4A-NS3 complexes of the invention, along with known synthetic substrates, to develop high throughput assays. These can be used to screen for compounds which inhibit
15 proteolytic activity of the protease. This is carried out by developing techniques for determining whether or not a compound will inhibit the covalent NS4A-NS3 complexes of the invention from cleaving the viral substrates. Examples of such synthetic substrates are set forth in SEQ ID NOs 25 and 93. If the substrates are not cleaved, the virus cannot
20 replicate. One example of such a high throughput assay is the scintillation proximity assay (SPA). SPA technology involves the use of beads coated with scintillant. Bound to the beads are acceptor molecules such as antibodies, receptors or enzyme substrates which interact with ligands or enzymes in a reversible manner.
25

- For a typical protease assay the substrate peptide is biotinylated at one end and the other end is radiolabelled with low energy emitters such as ¹²⁵I or ³H. The labeled substrate is then incubated with the enzyme. Avidin coated SPA beads are then added which bind to the
30 biotin. When the substrate peptide is cleaved by the protease, the radioactive emitter is no longer in proximity to the scintillant bead and no light emission takes place. Inhibitors of the protease will leave the substrate intact and can be identified by the resulting light emission which takes place in their presence.

- 35 Another type of protease assay, utilizes the phenomenon of surface plasmon resonance (SPR). A novel, high throughput enzymatic assay utilizing surface plasmon resonance technology has been

successfully developed. Using this assay, and a dedicated BIACore™ instrument, at least 1000 samples per week can be screened for either their enzymatic activity or their inhibitory effects toward the enzymatic activity, in a 96 well plate format. This methodology is readily adaptable
5 to any enzyme-substrate reaction. The advantage of this assay over the SPA assay is that it does not require a radiolabeled peptide substrate.

EXAMPLES

Several covalent NS4A-NS3 complexes have been constructed, purified, characterized and assayed for activity based on a cDNA clone containing an HCV Japanese (1b/BK) strain whose sequence is published
5 in Takamizawa *et al.*, 1991, *J. Virology* 65:1105-1113. DNA sequencing of the clone (BK 138-1) revealed four amino acid differences with the published sequence, at positions 66 (A->G), 86 (P->Q), 87 (K->A) and 147 (F->S) of the NS3 protein.

10 The present invention can be illustrated by the following non-limiting examples.

Reagents and General Methods

15 Plasmid pHCV-1b/BK can be derived from DNA fragments containing the entire DNA sequence of HCV BK cDNA as reported by Takamizawa *et al.*, 1991, *J. Virology* 65:1105-1113, with the above-mentioned changes. Plasmid pMD-34-2 is derived from that portion of the disclosed DNA sequence which encodes NS3 residues 1-631 from HCV BK cDNA.

20 Restriction Enzymes, Vent Polymerase and ThermoPol buffer were obtained from New England Biolabs (Beverly, MA). The QuickChange mutagenesis kit and dNTP's were obtained from Stratagene (LaJolla, CA). Ready-to-Go T4 DNA Ligase was obtained from Pharmacia Biotech (Piscataway, NJ). Oligonucleotide primers were synthesized by Genosys Biotechnologies (Woodland, Texas). DNA sequencing was performed according to the Sanger-Dideoxy method by
25 Bioserve Biotechnologies (Laurel, MD). pET vectors and BL21(DE3) cells were obtained from Novagen (Madison, WI). PCR reactions were carried out in a Perkin Elmer Cetus, model 480 DNA thermocycler. DH5 α cells and TAE buffer were purchased from Gibco, BRL. GTG agarose was purchased from FMC corporation. The Qiaquick gel extraction kit and Qiaquick PCR purification kit were purchased from
30 Qiagen Inc. (Chatsworth, CA).

Standard DNA recombinant DNA methods were carried out essentially as described by Sambrook et. al. in "Molecular Cloning: A Laboratory Manual," 2nd edition, 1989, Cold Springs Harbor Press, Plainview, New York.

5 Preparation of NS4A-Tethered Forms of HCV NS3 Protease

Native, NS4A-tethered forms of NS3 catalytic domain

10 Various NS4A-tethered forms of the NS3 catalytic domain were constructed by joining the NS4A peptide GSVVIVGRIILS (NS4A amino acids 21-32) to the amino terminus of NS3 amino acids 3-181 via various three or four residue linkers, and were cloned into the pET-28b+ vector.

15 Single stranded oligonucleotide primers were designed to generate a 616 base pair PCR fragment containing an NdeI site followed by the NS4A peptide, a linker, and amino acids 3-181 of the NS3 catalytic domain at the 5' terminus and a stop codon flanked by an EcoRI site at the 3' terminus. The template used was the sequence disclosed in Takamizawa, *et al*, 1991, *J. Virology* 65(3):1105-1113, which contains the entire HCV genome from the 1b/BK strain, except for the four differences described above. Other sources for HCV DNA can be used in
20 the disclosed methods, including plasmid pBRTM/HCV 1-3011 (Grakoui *et al.*, 1993), which contains the entire genome from the 1a strain.

25 Vent DNA polymerase was utilized to amplify the DNA by PCR. Primers were diluted in dH₂O to give a final concentration of 50 µg/ml. The template was diluted in dH₂O to give a final concentration of 10 ng/µl; The dNTP's (GTP, ATP, CTP, GGT) were diluted to a concentration of 10 mM (2.5 mM each) in dH₂O.

30 100 µl reactions were prepared for PCR in a 500 ul Eppendorf tube by addition of the following reagents: 74 µl of dH₂O, 10 µl of the 10x Thermopol buffer (final 1x buffer: 10 mM KCL, 20 mMTris-HCL (pH 8.8), 2mM MgSO₄ and 0.1% Triton X), 10 µl of template (100 ng), 2 µl of the 5' primer (100 ng); 1 µl of the 3' primer (50 ng), 2 µl of the dNTP mixture (200 µM) and 1 µl of Vent polymerase enzyme (1 unit). The mixture was

then overlayed with 20 ul of immersion oil and placed in the thermocycler for amplification. The PCR conditions were as follows: 95 °C for 45 seconds (1 cycle); 95 °C for 30 seconds, 55 °C for 1 minute, 72 °C for 2 minutes (25 cycles).

- 5 The amplified 616 base pair fragment was purified in preparation for restriction digestion using a Qiaquick PCR purification kit according to the manufacturer's protocol without modification. Briefly, the aqueous layer was removed and placed in a 1.5 ml Eppendorf tube with a reagent that aids the DNA to bind to a column matrix. The DNA was
10 washed while bound to the column and then eluted with 43 µl of H₂O. The DNA was then double digested with EcoRI and NdeI in a 50 ul volume for 1 hour at 37 °C. The reaction took place in a 1.5 ml polypropylene Eppendorf tube with 5 µl of 10x EcoRI buffer (final concentration of 50mM NaCl, 100 mM Tris-HCL, 10mM MgCl₂, 0.25%
15 Triton X-100, pH 7.5) and µ1 l of EcoRI and NdeI (20 units). The pET-28b+ vector (3 µg) was also digested using the same conditions. The digests were further purified by resolving them on a 1.0 % agarose electrophoresis gel for 45 minutes under 100 volts. They were rendered visible with 0.5 µg/ml of ethidium bromide, excised with a scalpel under
20 short-wave UV, solubilized and purified using the QIAquick gel extraction kit according to manufacturer's protocol without modifications. The fragments were quantitated by visually comparing a 5 ul aliquot of the purified fragment versus Lambda Hind/III DNA standards on a 1% agarose gel. Approximately 200 ng of vector and 50 ng
25 of PCR fragment were ligated together in a 20 ul volume for 18 hours at 16 degrees. They were combined together in a T4 ligase (Ready-to-Go) reaction tube according to standard protocol without modifications.

- 30 2 µl of this mixture was then used to transform 50 µl of DH5 α cells for plasmid propagation according to manufacturer's protocol. Briefly, a 1.5 ml Eppendorf tube was placed on ice and 50 ul of DH5 α cells (previously stored at -80°C and then thawed on ice immediately prior to use) were added to the tube along with the 2 ul of ligation mixture and allowed to incubate for 30 minutes. They were then heat shocked for 1 minute at 42°C, returned to the ice for 2 minutes and then regenerated
35 with 500 µl of SOC medium and incubated at 37°C for 1 hour at 300 rpm.

200 μ l of these cells were then plated out on LB/20-10-5 agar (per liter: tryptone 50 grams, yeast extract 25 grams, NaCl 12.5 gram) with kanamycin (25 μ g/ml), spread for single colony isolation and incubated at 37 °C overnight. Three single colonies were selected for plasmid
5 preparations. They were inoculated into 100 mls of LB/20-10-5 broth with kanamycin (25 μ g/ml) in a 250 ml baffled flask and grown overnight for 18 hours at 37 degrees at 300 RPM in a shaker. The next day, the cultures were spun down in 500 ml Nalgene centrifuge bottles (8000 RPM, 10 minutes, 4 °C) and the pellet was harvested for plasmid
10 isolation. The Qiagen midi-prep kit was used according to manufacturer's protocol. The DNA was quantitated using a UV/VIS spectrophotometer (Perkin-Elmers) at 260 nm. The purified, plasmid-DNA isolates were sequenced on an Applied Biosystems 373A DNA sequencer at Bioserve Biotechnologies, Inc. To confirm the sequence,
15 both top and bottom strands were sequenced via primers that were synthesized by Bioserve Biotechnologies.

Native, NS4A-tethered forms of NS3 full-length domain

Both parental plasmids, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ and HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ /S139A parental plasmids were created via a cut
20 and paste method. Briefly, 5 μ l of plasmid PMD34-2 (1 μ g), plasmid HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ (5 μ g) and plasmid HIS-NS3₁₋₆₃₁/S139A (1 μ g)
and were each digested separately in a 1.5 ml Eppendorf tube with 5 μ l of NEB buffer #2 (at final concentration of 10mM Tris-HCL, 10mM MgCl₂,
25 50mM NaCl, 1mM DTT, pH 7.9), 0.5 μ l of acetylated BSA (final concentration 100 μ g/ml), 1 μ l of XbaI (2 Units) and 38.5 μ l of ddH₂O.

These digests were incubated at 37 °C for one hour at which time 2.5 μ l of 2M NaCl (final concentration of 150mM) 45 μ l of ddH₂O and 2.5 μ l of BspMI (2 Units) were added to the digests and incubated for 2 more hours at 37 °C. The double digests were then resolved on 0.8 % agarose
30 gels and the size and quantity of the fragments were determined. The agarose gels were electrophoresed in BioRad apparatus and the fragments were excised using a scalpel. The excised backbone fragments which were derived from PMD34-2 and HIS-NS3₁₋₆₃₁/S139A were each 7.1 KB and the insert from HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ was 275 base
35 pairs. Approximately 2 μ l of 7.1 KB backbone (200 ng) and 1 μ l of 225 bp

insert (50 ng) were ligated together in a 20 μ l volume for 18 hours at 16 °C. They were combined together in a T4 ligase (Ready-to-Go) reaction tube according to standard protocol without modifications. 2 μ l of this mixture was then used to transform 50 μ l of DH5 α cells for plasmid propagation according to manufacturer's protocol.

- Three single colonies of each construct were selected for miniprep plasmid isolations using a Qiagen miniprep kit. They were inoculated into 5 mls of LB/20-10-5 broth with ampicillin (100 μ g/ml) in a 15 ml tubes and grown overnight for 18 hours at 37°C at 300 RPM in a shaker.
- 5 The next day, the cultures were spun down 3000 RPM, 10 minutes, 4°C and the pellet was harvested for plasmid isolation. The clones were then assessed for recombination by digesting with BspMI and XbaI according to the conditions described above. The digests were resolved on a 1% agarose gel and only those constructs yielding a 225 bp and 7.1
- 10 KB bp fragment were chosen as positives. Cultures from the positive clones were inoculated into 100 mls of LB/20-10-5 broth with ampicillin (100 μ g/ml) in a 250 ml baffled flask and grown overnight for 18 hours at 37°C at 300 RPM in a shaker. The next day, the cultures were spun down in 500 ml Nalgene centrifuge bottles (8000 RPM, 10 minutes, 4°C)
- 15 and the pellet was harvested for plasmid isolation. The Qiagen midi-prep kit was used according to manufacturer's protocol. The DNA was quantitated using a UV/VIS spectrophotometer (Perkin-Elmers) at 260 nm. The purified plasmid-DNA isolates were sequenced at the restriction site junctions on an Applied Biosystems 373A DNA sequencer at Bioserve Biotechnologies, Inc.
- 20 25

Site-directed Mutants.

All site-directed mutations created in either NS4A-tethered forms of catalytic or full-length domain of NS3 protease were carried out using the quikchange site-directed mutagenesis kit (Stratagene) according to the manufacturer's protocol. For each mutation, two oligonucleotide primers (10 picomoles each) containing the desired mutation were used to amplify the entire plasmid encompassing the NS4A-tethered NS3 protease gene (50 or 100 ng/reaction) using pfu DNA polymerase (2.5 units/reaction) in a final reaction volume of 50 μ l. The PCR conditions were as follows: 95 °C for 45 seconds (1 cycle); 95 °C for 30 seconds, 55 °C

for 1 minute, 68 °C for 15 minutes (16 cycles). After amplification, the reaction mixture was treated with 1 ul of DpnI (1 Unit) for 1 hour at 37 °C in order to digest the parental DNA.

- One microliter of this digest was used to transform 50 µl of XLI
5 Blue cells to repair nicks and propagate the mutated plasmid. Plasmid-DNA were purified and transformed into BL21 (DE3) cells for expression studies.

EXAMPLE 1

10 NS3 Catalytic Domain Constructs

i. **HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ (SEQ ID NO: 1)**

HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ was constructed by joining amino acids 21-32 of the NS4A peptide to the N-terminal domain of NS3 protease (NS3 amino acids 3-181) via the linker GSGS (SEQ ID NO: 21),
15 and was cloned into the pET-28b+ vector as described above. The 5' primer reads as follows:

5'GATATACATATGGGTTCTGTTGTTATTGTTGGTAGAAATTATTTATCT
GGTAGTGGTAGTATCACGGCCTACTCCCAA 3' (SEQ ID NO:26).

The 3' primer reads as follows:

20 5' CTCAGCGAATTCTCAAGACCGCATAGTAGTTCCAT 3' (SEQ ID NO:27).

ii. **HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I17K (SEQ ID NO: 2)**

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ was
constructed by creating a point mutation at position 17 of the NS3
25 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template were regenerated which contain the point mutation which

alters amino acid number 17 (isoleucine) to a lysine. The top strand primer was as follows:

5'CGGGGCCTACTTGGTTGCAAGATCACTAGCCTTACAGGC 3'

5 (SEQ ID NO:28).

The bottom strand read as follows:

5' GCCTGTAAGGCTAGTGTATCTTGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 29).

10 The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁, along with these two primers, were utilized in a PCR reaction to generate the point mutation.

(iii) HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K (SEQ ID NO: 3)

15 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ was constructed by creating a point mutation at position 18 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine. The top 20 strand primer was as follows:

5' CGGGGCCTACTTGGTTGCATCAAGACTAGCCTTACAGGC 3'

(SEQ ID NO: 30).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGCCCG 3'

25 (SEQ ID NO: 31).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁, along with these two primers was utilized in a PCR reaction to generate the point mutation.

(iv) HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I17K, I18K (SEQ ID NO: 4)

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K was constructed by creating a point mutation at position 17 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine.

5 The top strand primer was as follows:

5' CGGGGCCTACTGGTTGCAAGAAGACTAGCCTTACAGGC 3'
(SEQ ID NO:32).

10 The bottom strand read as follows:

5' GCCTGTAAGGCTAGTCTTCTGCAACCAAGTAGGCCCG 3'.
(SEQ ID NO:33)

The template HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K, along with these two primers, was utilized in a PCR reaction to generate the point mutation.

15

v. **HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A (SEQ ID NO: 5)**

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ was constructed by creating a point mutation at position 139 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ construct as described above.

20 Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 139 (catalytic serine) to an alanine. The top strand primer was as follows:

5' CTCCTACTGAAGGGCTCTGCTGGTGGTCCACTGCTCTGC 3'
25 (SEQ ID NO:34).

The bottom strand reads as follows:

5' GCAGAGCAGTGGACCACCAGCAGAGGCCCTCAAGTAGGAG 3'
(SEQ ID NO:35).

The template HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁, along with these two primers, was utilized in a PCR reaction to generate the point mutation.

vi. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I17K (SEQ ID NO: 6)

5 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A was constructed by creating a point mutation at position 17 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/ S139A construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 17 (isoleucine) to a lysine.

10 The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGATCACTAGCCTTACAGGC 3'
(SEQ ID NO:36).

The bottom strand reads as follows:

15 5' GCCTGTAAGGCTAGTGATCTTGCACCCAAGTAGGCCCG 3'
(SEQ ID NO:37).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

vii. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I18K (SEQ ID NO: 7)

20 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A was constructed by creating a point mutation at position 18 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine.

25 The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCATCAAGACTAGCCTTACAGGC 3'
(SEQ ID NO:38).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGCCCG 3'

(SEQ ID NO:39).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A along with these two primers was utilized in a PCR reaction to generate this point mutation.

5 viii. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I17K, I18K (SEQ ID NO. 8)

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I17K was constructed by creating a point mutation at position 18 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A,I17K construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGAAGACTAGCCTTACAGGC 3'

(SEQ ID NO: 40).

15 The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 41).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A,I17K, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

ix. HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁ (SEQ ID NO: 9)

An NS4A-tethered form of the NS3 catalytic domain, HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁, was constructed by joining the NS4A peptide GSVVIVGRIILS (NS4A amino acids 21-32) to the N-terminal domain of 25 NS3 protease (NS3 amino acids 3-181) via the linker PAGG (SEQ ID NO: 22), and was cloned into the pET-28b+ vector as described above. Primers were designed to generate a 616 base pair PCR fragment containing an NdeI site followed by the NS4A peptide, the PAGG linker, and amino acids 3-181 of the NS3 catalytic domain at the 5' terminus and a stop

codon flanked by an EcoRI site at the 3' terminus. The 5' primer reads as follows:

5' GATATACATATGGGTTCTGGTATTGGTAGAATTATTT

ATCTCCTGCTGGTGGTATCACGGCCTACTCCAA 3' (SEQ ID NO: 42).

- 5 The 3' primer reads as follows:

5' CTCAGCGAATTCTCAAGACCGCATAGTAGTTCCAT 3' (SEQ ID NO: 43).

10 Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert encoding HIS-NS3 (1-631) from 1b/BK strain was used as the template for PCR.

x. **HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁/I17K (SEQ ID NO: 10)**

15 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁ was constructed by creating a point mutation at position 17 of the NS3 domain of the HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 17 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGGTGCAAGATCACTAGCCTTACAGGC 3'

20 (SEQ ID NO: 44).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTGATCTGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 45).

25 The template, HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁, along with these two primers was utilized in a PCR reaction to generate this point mutation.

xi. **HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁ (SEQ ID NO: 46)**

A NS4A-tethered form of the NS3 catalytic domain, HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁, was constructed by joining the NS4A peptide GSVVIVGRIILS (NS4A amino acids 21-32) to the N-terminal domain of NS3 protease (NS3 amino acids 3-181) via the linker PAG (SEQ ID NO: 47), and was cloned into the pET-28b+ vector as described above. Primers were designed to generate a 613 base pair PCR fragment containing an NdeI site followed by the NS4A peptide, the PAG linker, and amino acids 3-181 of the NS3 catalytic domain at the 5' terminus and a stop codon flanked by an EcoRI site at the 3' terminus. The 5' primer reads as follows:

5' GATATACATATGGGTTCTGTTATTGTTGGTAGAATTATTT

ATCTCCTGCTGGTATCACGGCCTACTCCAA 3' (SEQ ID NO: 48).

The 3' primer reads as follows:

5' CTCAGCGAATTCTCAAGACCGCATAGTAGTTCCAT 3'

15 (SEQ ID NO: 49).

Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert encoding HIS-NS3 (1-631) from 1b/BK strain was used as the template for PCR.

xii. **HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁/I17K (SEQ ID NO: 50)**

20 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁ was constructed by creating a point mutation at position 17 of the NS3 domain of HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template were generated which contains the point mutation 25 which alters amino acid residue number 17 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGTTGCAAGATCACTAGCCTTACAGGC 3'

(SEQ ID NO: 51).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTGATCTTGCACCCAAGTAGGCCCG 3'

(SEQ ID NO: 52).

The template, HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁ along with these two primers were utilized in a PCR reaction to generate this point mutation.

5 xiii. HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁ (SEO ID NO: 53)

An NS4A-tethered form of NS3 catalytic domain, HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁ was constructed by joining the NS4A peptide GSVVTVGRIILS (NS4A amino acids 21-32) to the N-terminal domain of NS3 protease (NS3 amino acids 3-181) via the linker GGS (SEQ ID NO: 54), and was cloned into the pET-28b+ vector as described above. Primers were designed to generate a 613 base pair PCR fragment containing an NdeI site followed by the NS4A peptide, the GGS linker, and amino acids 3-181 of the NS3 catalytic domain at the 5' terminus and a stop codon flanked by an EcoRI site at the 3' terminus. The 5' primer reads as follows:

5' GATATACATATGGGTTCTGTTATTGTTGGTAGAATTATTT

ATCTGGTGGTCTATCACGGCCTACTCCCAA 3' (SEQ ID NO: 55).

The 3' primer reads as follows:

5' CTCAGCGAATTCTCAAGACGGCATACTAGTTTCCAT 3'

20 (SEO ID NO: 56).

Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert encoding HIS-NS3 (1-631) from 1b/BK strain was used as the template for PCR.

xiv. HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁/I17K (SEO ID NO: 57)

25 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁ was constructed by creating a point mutation at position 17 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation

which alters amino acid number 17 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGATCACTAGCCTACAGGC 3'
(SEQ ID NO: 58).

5 The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTGATCTTGCACCAAGTAGGCCCG 3'
(SEQ ID NO: 59).

The template, HIS-NS4A₂₁₋₃₂-GGS-NS3₃₋₁₈₁, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

10

EXAMPLE 2

NS3 Full-Length Constructs

i. HIS-NS3₁₋₆₃₁/I17K (SEQ ID NO: 60)

15 A single amino acid mutant of HIS-NS3₁₋₆₃₁ was formed by creating a point mutation at position 17 of NS3 protease using the Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS- NS3₁₋₆₃₁ from 1b/BK strain as described above. Two oligonucleotide internal primers, each complementary to opposite strands of the template, were generated which contain the point 20 mutation which alters amino acid number 17 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGATCACTAGCCTACAGGC 3'
(SEQ ID NO: 61).

The bottom strand reads as follows:

25 5' GCCTGTAAGGCTAGTGATCTTGCACCAAGTAGGCCCG 3'
(SEQ ID NO: 62).

The template, plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain, along with these two primers was utilized in a PCR reaction to generate this point mutation.

5 ii. HIS-NS3₁₋₆₃₁/I18K (SEQ ID NO: 63)

A single amino acid mutant of HIS-NS3₁₋₆₃₁ was formed by creating a point mutation at position 18 of NS3 protease using the Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain as described above. Two oligonucleotide internal primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine. The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCATCAAGACTAGCCTTACAGGC 3'

15 (SEQ ID NO: 64).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGGCCCCG 3'

(SEO ID NO: 65).

The template, plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain along with these two primers was utilized in a PCR reaction to generate this point mutation.

iii. HIS-NS3₁₋₆₃₁/S139A (SEQ ID NO: 66)

25 A single amino acid mutant of HIS-NS3₁₋₆₃₁ was formed by
creating a point mutation at position 139 of the NS3 protease using the
Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing
the gene insert, encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain as described
above. Two oligonucleotide internal primers, each complementary to
opposite strands of the template, were generated which contain the point
mutation which altered amino acid number 139 (catalytic serine) to an
alanine. The top strand primer was as follows:
30

5' CTCCTACTTGAAGGGCTCTGCTGGTGGTCCACTGCTCTGC 3'

(SEQ ID NO: 67).

The bottom strand reads as follows:

5' GCAGAGCAGTGGACCACCAAGCAGAGCCCTCAAGTAGGAG 3'

5 (SEQ ID NO: 68).

The template, plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS₃₁₋₆₃₁ from 1b/BK strain along with these two primers was utilized in a PCR reaction to generate this point mutation.

10 iv. HIS-NS₃₁₋₆₃₁/I403S (SEQ ID NO: 69)

A single amino acid mutant of HIS-NS₃₁₋₆₃₁ was formed by creating a point mutation at position 403 of the NS3 protease using the Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS₃₁₋₆₃₁ from 1b/BK strain as described above. Two oligonucleotide internal primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 403 (isoleucine) to a serine. The top strand primer was as follows:

5' GTCCGTCATACCAACTTCCGGAGACGTCGTTGTCG 3'

20 (SEQ ID NO: 70).

The bottom strand reads as follows:

5' CGACAACGACGTCTCCGGAAGTTGGTATGACGGAC 3'

(SEQ ID NO: 71).

25 The template, plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS₃₁₋₆₃₁ from 1b/BK strain along with these two primers was utilized in a PCR reaction to generate this point mutation.

v. HIS-NS₃₁₋₆₃₁/NdeI (SEQ ID NO. 72)

A silent mutant of HIS-NS3₁₋₆₃₁ was formed to eliminate the internal NdeI restriction site within NS3 protease using the Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain as described above. Two 5 oligonucleotide internal primers, each complementary to opposite strands of the template, were generated which contain point mutations which alters the codons on the reading strand of alanine 217 from GCA to GCC and tyrosine 218 from TAT to TAC. The top strand primer was as follows:

10 5' ACTAAAGTGCCGGCTGCCTACGCAGCCCAAGGG 3'

(SEQ ID NO: 73).

The bottom strand reads as follows:

5' CCCTTGGGCTGCGTAGGCAGCCGGCACTTTAGT 3'

(SEQ ID NO: 74).

15 The template, plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert encoding HIS-NS3₁₋₆₃₁ from 1b/BK strain, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

vi. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ (SEQ ID NO: 4)

20 An NS4A-tethered form of the NS3 full-length domain, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁, was constructed via a cut and paste strategy as described above. Briefly, a 270 bp fragment was generated by restricting HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ with XbaI/BspMI; This fragment encompassed sequences encoding a histidine tag followed by a thrombin 25 site, the NS4A peptide, GSVVIVGRIILS (NS4A amino acids 21-32), the linker GSGS (SEQ ID NO: 21) and NS3 amino acids 3-48. A second 7111 fragment (7111 bp) was generated by restricting Plasmid-DNA (PMD-34-2), comprised of pET-22b+ vector encompassing the gene insert, encoding HIS-NS3 (1-631) from 1b/BK strain with XbaI/BspMI resulting 30 in a fragment encompassing the pET 22b+ vector backbone in addition to amino acids 49- 631. These two fragments were then ligated together with T4 DNA ligase to form HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁.

vii. **HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/I17K (SEQ ID NO: 12)**

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ was constructed by creating a point mutation at position 17 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 17 (isoleucine) to a lysine. The top strand primer was as follows:

10 5' CGGGGCCTACTTGGTTGCAAGATCACTAGCCTTACAGGC 3'
(SEQ ID NO: 75).

The bottom strand read as follows:

5' GCCTGTAAGGCTAGTGATCTTGCAACCAAGTAGGCCCG 3'
(SEQ ID NO: 76).

15 The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ along with these two primers was utilized in a PCR reaction to generate this point mutation.

viii. **HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/I18K (SEQ ID NO: 13)**

A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ was constructed by creating a point mutation at position 18 of the NS3 domain of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template were generated which contained the point mutation which alters amino acid number 18 (isoleucine) to a lysine. The top strand primer was as follows:

25 5' CGGGGCCTACTTGGTTGCATCAAGACTAGCCTTACAGGC 3'
(SEQ ID NO: 77).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 78).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁, along with these two primers was utilized in a PCR reaction to generate this point mutation.

ix. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/I17K, I18K (SEQ ID: 14)

- 5 A double amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ was constructed by creating 2 point mutations at positions 17 and 18 of the NS3 domain of the HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ construct simultaneously as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated
10 which contain the point mutations which alter amino acid numbers 17 (isoleucine) and 18 (isoleucine) to lysines. The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGAAGACTAGCCTTACAGGC 3'

(SEQ ID NO: 79).

- 15 The bottom strand read as follows:

5' GCCTGTAAGGCTAGTCTTCTTGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 80).

The template, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

20 **x. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A (SEQ ID NO: 15)**

- An NS4A-tethered form of NS3 full-length domain, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, was constructed via a cut and paste strategy as described above. Briefly, a 290 bp fragment was generated by restricting HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁ with XbaI/BspMI; this fragment encompasses sequence encoding a histidine tag, a thrombin site, amino acids 21-32 of the the NS4A peptide, the linker GSGS (SEQ ID NO. 21) and NS3 amino acids 3-48. A second 7111 fragment (7111 bp) was generated by restricting HIS-NS3₁₋₆₃₁/S139A construct with XbaI/BspMI resulting in a fragment encompassing the pET 22b+ vector backbone in addition to amino acids
25

49- 631. These two fragments were then ligated together with T4 DNA ligase to form HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A.

xi. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I17K (SEQ ID NO: 16)

5 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A was constructed by creating a point mutation at position 17 of the NS3 domain of the HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 17 (isoleucine) to a lysine.
10 The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCAAGATCACTAGCCTTACAGGC 3'

(SEQ ID NO: 81).

The bottom strand is as follows:

15 5'GCCTGTAAGGCTAGTGATCTTGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 82).

The template HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

xii. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I18K (SEQ ID NO: 17)

20 A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A was constructed by creating a point mutation at position 18 of the NS3 domain of the HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to a lysine.
25 The top strand primer was as follows:

5' CGGGGCCTACTTGGTTGCATCAAGACTAGCCTTACAGGC 3'

(SEQ ID NO: 83).

The bottom strand read as follows:

5' GCCTGTAAGGCTAGTCTTGATGCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 84).

- 5 The template HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, along with these two primers, was utilized in a PCR reaction to generate this point mutation.

xiii. HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I17K, I18K (SEQ ID NO: 18)

- A single amino acid mutant of HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I17K was constructed by creating a point mutation at position 18 of the NS3 domain of the HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I17K construct as described above. Two oligonucleotide primers, each complementary to opposite strands of the template, were generated which contain the point mutation which alters amino acid number 18 (isoleucine) to an lysine. The top strand primer was as follows:

5' CGGGGCCTACTGGTTGCAAGAAGACTAGCCTTACAGGC 3'

- 15 (SEQ ID NO: 85).

The bottom strand reads as follows:

5' GCCTGTAAGGCTAGTCTTGTCAACCAAGTAGGCCCG 3'

(SEQ ID NO: 86).

- 20 The template HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A,I17K, along with these two primers was utilized in a PCR reaction to generate this point mutation.

xiv. HIS-NS4A₁₅₋₃₂-GSGS-NS3₃₋₆₃₁ (SEQ ID NO: 19)

- A NS4A-tethered form of NS3 full-length domain, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ was constructed by joining the amino acids 15-32 of NS4A peptide to the N-terminal end of the NS3 protease (NS3 amino acids 3-631) via the linker GSGS, and was cloned into the pET-28b+ vector as described above with the following modification. Primers were designed to generate a PCR fragment containing an NdeI site followed by the NS4A peptide, the GSGS linker (SEQ ID NO: 21), and amino acids 3-631

of the NS3 catalytic domain at the 5' terminus and a stop codon flanked by an EcoRI site at the 3' terminus. The 5' primer sequence was as follows:

5'GATATACATATGGCTTACTCTCTGACTACGGTTCTGTTATT
5 GTGGTAGAATTATTTATCTGGTAGTGGTAGTACGGCCTACTCCAA 3'
(SEQ ID NO: 87).

The 3' primer sequence was as follows:

5' GTGGTGGTGCTCGAGGCTGCCGCGCGCA
CCAGCGTAACGACCTCCAGGT 3' (SEQ ID NO: 88).

- 10 The template used was HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁. The resulting PCR fragment was 1974 bases. Vent DNA polymerase was employed and a final concentration of 200 μM dNTPS was used. The PCR conditions were as follows: 95 °C for 45 seconds (1 cycle); 95 °C for 30 seconds, 55 °C for 1 minute, 72 °C for 2 minutes (25 cycles). The product
15 was purified with QIAquick PCR kit (Qiagen). This PCR product, along with the 6.6 kb vector backbone (HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁), were double digested with NdeI and BamHI. The digested fragments of 1.43 and 6.6 Kbp respectively were run on agarose gel, excised, and column purified with QIAquick gel extraction kit (Qiagen). They were
20 quantitated and then ligated together with T4 DNA ligase.

xv. HIS-NS4A₁₅₋₃₂-GSGS-NS3₃₋₆₃₁/S139A (SEQ ID NO: 20)

An NS4A-tethered form of NS3 full-length domain, HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A was constructed by joining amino acids 15-32 of the NS4A peptide to the N-terminal end of the NS3 protease (NS3 amino acids 3-631) via the linker GSGS (SEQ ID NO: 21), and was cloned into the pET-28b+ vector as described above with the following modification. Primers were designed to generate a PCR fragment containing an NdeI site followed by the NS4A peptide, the GSGS linker (SEQ ID NO: 21), and amino acids 3-631 of the NS3 catalytic domain at the 5' terminus and a stop codon flanked by an EcoRI site at the 3' terminus. The 5' primer sequence was as follows:

5'GATATACATATGGCTTACTCTCTGACTACGGTTCTGTTATT
GTGGTAGAATTATTTATCTGGTAGTGGTAGTACGGCCTACTCCAA 3'
(SEQ ID NO: 89).

The 3' primer reads as follows:

5 5' TGGTGGTGCTCGAGGCTGCCGCGGCACCAGCGTAACGACCT
CCAGGTC 3' (SEQ ID NO: 90).

The template used was HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A. The resulting PCR fragment was 1974 bases. Vent DNA polymerase was employed and a final concentration of 200 μM dNTPS was used. The 10 PCR conditions were as follows: 95 °C for 45 seconds (1 cycle); 95 °C for 30 seconds, 55 °C for 1 minute, 72 °C for 2 minutes (25 cycles). The product was purified with QIAquick PCR kit (Qiagen). This PCR product along with the 6.6 kb vector backbone (HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁) were double digested with NdeI and BamHI. The digested fragments of 15 1.43 and 6.6 Kbp respectively were run on agarose gel, excised, and column purified with QIAquick gel extraction kit (Qiagen). They were quantitated and then ligated together with T4 DNA ligase.

EXAMPLE 3

20 Expression and Purification of HCV NS4A-NS3 Complexes

A. *Small Scale Expression Studies*

All constructed plasmids were transformed into DH5α cells for production of large amount of plasmid-DNA. The purified plasmid-DNA was transformed into BL21(DE3) cells for expression studies. The 25 cells were grown in Terrific Broth in baffled flasks at 37°C to an OD of 1.0 and the temperature was lowered to 23°C. The cultures were induced with 0.4 mM IPTG and were harvested 3 hours after induction. Cells were sonicated for 1 min in 50 mM HEPES, pH 7.5, 20% glycerol, 0.1% βOG, 0.3 M NaCl, 10 mM βME and spun at 13,000 rpm for 10 min. The 30 supernatants were analyzed on 10% Novex SDS-PAGE.

B. Large-Scale Expression And Purification Of NS4A-Tethered Forms Of HCV NS₃₋₁₈₁ Protease

E. coli, BL21(DE3) cells harboring either plasmid pET-22b or pET-28b encoding various native, single, or multiple mutants of NS4A-tethered forms of NS3₁₋₁₈₁ were grown at 37°C in Terrific Broth supplemented with either 100 ug/ml of ampicillin (for pET-22b) or 25 ug/ml kanamycin (for pET28-b) in 10-liter fermentor. When the cell density reaches an OD of 2-3, the temperature was lowered to 23°C within 5 minutes and cells were induced with 0.4 mM IPTG. Cells were harvested 3 hours after induction and frozen at -20 °C prior to purification.

Cell pellets were resuspended in 600 ml of lysis buffer containing 50 mM HEPES, pH 7.4, 10% glycerol, 0.3 M NaCl, 0.1% βOG, 2 mM βME (buffer A), homogenized using a cell homogenizer (Omni Mixer ES) for 2 min and the cells were disrupted by two passes through a Microfluidizer (Microfluidics Model #M-110F) at 10,000 p.s.i. The lysate was centrifuged at 85,000 x g for 45 min. The supernatant was filtered through 0.8 micron filter units (Nalgene) and applied at 40 ml/min to a 11-ml Ni-imidodiacetate (POROS 20 MC resin) column in the presence of 20 mM imidazole on BIOCAD (Perseptive Biosystems). The column was washed with 10 column volumes of buffer A, followed by 15 column volume of buffer A containing 1.0 M NaCl and 20 mM imidazole (buffer B). The bound protease was eluted with the elution buffer (buffer B containing 250 mM imidazole). The eluted fractions containing the protease were pooled and dialyzed versus 16 liters of 50 mM HEPES, pH 7.4, 10% glycerol, 1 M NaCl, 10 mM βME in order to remove the imidazole and the detergent.

When the removal of the N-terminal histidine tag was required, human thrombin (Enzyme Research) was added to the eluted, pooled fractions at a thrombin:protease ratio of 8 units per mg of protease and thrombin cleavage was allowed to proceed during the dialysis step for 18 hours. The dialyzed, thrombin-cleaved protease was applied to 3 sephacryl-100 sizing column (26 x 60cm, Pharmacia) in series, equilibrated in of 50 mM HEPES, pH 7.4, 10% glycerol, 1 M NaCl, 10 mM βME at 0.5 ml/min. Fractions containing purified protease at above

>95% homogeneity as judged by SDS-PAGE were pooled and flash-frozen at -80 °C

C. *Large-Scale Expression And Purification Of NS4A-Tethered Forms Of HCV NS3₃₋₆₃₁ Protease*

5 E. coli, BL21(DE3) cells harboring either plasmid pET-22b or pET-28b encoding various native, single, or multiple mutants of NS4A-tethered forms of NS3₁₋₁₈₁ were grown at 37°C in Terrific Broth supplemented with either 100 µg/ml of ampicillin (for pET-22b) or 25 µg/ml kanamycin (for pET28-b) in 10-liter fermentor. When the cell
10 density reaches an OD of 2-3, the temperature was lowered to 23°C within 5 minutes and cells were induced with 0.4 mM IPTG. Cells were harvested 3 hours after induction and frozen at -20 °C prior to purification.

15 Cell pellets were resuspended in 600 ml of lysis buffer containing 50 mM HEPES, pH 7.4, 10% glycerol, 0.3 M NaCl, 0.1% βOG, 2 mM βME (buffer A), homogenized using a cell homogenizer (Omni Mixer ES) for 2 min and the cells were disrupted by two passes through a Microfluidizer (Microfluidics Model #M-110F) at 10,000 p.s.i. The lysate was centrifuged at 85,000 x g for 45 min. The supernatant was filtered
20 through 0.8 micron filter units (Nalgene) and applied at 40 ml/min to a 11-ml Ni-imidodiacetate (POROS 20 MC resin) column in the presence of 20 mM imidazole on BIOCAD (Perseptive Biosystems). The column was washed with 10 column volumes of buffer A, followed by 15 column volume of buffer A containing 1.0 M NaCl and 20 mM
25 imidazole (buffer B). The bound protease was eluted with the elution buffer (buffer B containing 250 mM imidazole). The eluted fractions containing the protease were pooled and dialyzed versus 16 liters of 50 mM HEPES, pH 7.4, 10% glycerol, 1 M NaCl, 10 mM βME in order to remove the imidazole and the detergent.

30 When the removal of the N-terminal histidine tag was required, human thrombin (Enzyme Research) was added to the eluted, pooled fractions at a thrombin:protease ratio of 8 units per mg of protease and thrombin cleavage was allowed to proceed during the dialysis step for 18 hours. The dialyzed, thrombin-cleaved protease was applied to 3
35 sephacryl-100 sizing column (26 x 60cm, Pharmacia) in series,

equilibrated in of 50 mM HEPES, pH 7.4, 10% glycerol, 1 M NaCl, 10 mM β ME at 0.5 ml/min. Fractions containing purified protease at above >95% homogeneity as judged by SDS-PAGE were pooled and flash-frozen at -80 °C.

5

EXAMPLE 4

**Molecular Weight Determination Of Various NS3 Protease Forms
By Size Exclusion Chromatography**

Two hundred μ l of various purified proteins were applied to a calibrated Superdex-75 HR (1cm x 30 cm) FPLC column equilibrated with 10 25 mM HEPES, pH 7.4, 1M NaCl and 10% glycerol and 10 mM β ME at 0.5 ml/min. The column was precalibrated using Pharmacia standard calibration proteins (BSA: 67 KDa; Ovalbumin: 43 KDa; Chymotrypsinogen A: 31 KDa; Ribonuclease A: 13.7 KDa). Protein elution was monitored at 280 nm.

15

The following covalent NS4A-NS3 complexes described above were characterized by the above method:

- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I17K
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/I18K
- 20 HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I17K
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₁₈₁/S139A, I18K

- HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁
- HIS-NS4A₂₁₋₃₂-PAGG-NS3₃₋₁₈₁/I17K

- 25 HIS-NS4A₂₁₋₃₂-PAG-NS3₃₋₁₈₁/I17K

- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁.
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/I17K
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/I18K
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A
- 30 HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I17K
- HIS-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁/S139A, I18K

Of those constructs characterized, all covalent NS4A-NS3 complexes containing a three amino acid linker resulted in aggregated forms, as judged by size exclusion chromatography. NS4A-tethered forms in which a point mutation at position 17 or 18 had not been introduced also resulted in aggregated forms, although they exhibited activity identical to that of the monodisperses forms of the protease.

Covalent NS4A-NS3 complexes which contained a four amino acid linker and a point mutation at position 17 and/or 18 resulted in active, monodisperses proteins with apparent molecular weights smaller than predicted as determined by size exclusion chromatography.

EXAMPLE 5
Determination of Proteolytic Activity

Following expression and purification, newly engineered recombinant species were assayed for proteolytic activity utilizing a 1D-HPLC (reverse-phase chromatography) technique. Assays were conducted using the 5A/5B (P8P8') substrate DTEDVVCC*SMSYTWTG-K (SEQ ID NO: 25) in 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 10 mM DTT, 10% glycerol, and 0.05% lauryl maltoside. Concentration of all proteins were determined by BIORAD dye method).

The catalytic domain His-NS3₁₋₁₈₁ (batch # 51072-92E) was preincubated at a concentration of 250 nM in the presence of 20 µM 4A peptide (KKGSVVIVGRIVLSGKPAIIPKK) for 15 minutes at 4°C. This mixture was then diluted into the reaction volume at a final concentration of 8 µM 4A peptide and 100 nM catalytic domain. Reactions were incubated at room temperature for 60 minutes and were quenched with an equal volume of 10% phosphoric acid. Following injection, cleavage products were monitored under a linear 0-80% acetonitrile gradient in 0.1% TFA. The product P1'P8'K peak areas were automatically converted to product quantity in nanomoles by a standard curve.

The various covalent NS4A-NS3 complexes whose proteolytic efficiency has been determined according to the above method, and the results of each determination, are shown in Table 1.

Table 1.
35 Catalytic Efficiency Of Various Forms Of NS3 Protease

Construct	k_{cat} (min ⁻¹)	K _m (μM)	k_{cat}/K_m (M ⁻¹ s ⁻¹)
NS3 ₁₋₆₃₁ -NS4A ₁₋₅₄	10 ± 2	20 ± 2	(8 ± 2) × 10 ³
His-NS3 ₁₋₁₈₁ + NS4A Peptide ^a	3 ± 1	80 ± 20	(0.5 ± 0.2) × 10 ³
His-NS4A ₂₁₋₃₂ -GSGS-NS3 ₃₋₁₈₁	9 ± 2	19 ± 3	(8 ± 2) × 10 ³
His-NS4A ₂₁₋₃₂ -GSGS-NS3 ₃₋₁₈₁ /I17K	16 ± 3	20 ± 2	(14 ± 2) × 10 ³
His-NS4A ₂₁₋₃₂ -GSGS-NS3 ₃₋₁₈₁ /I18K	10 ± 2	22 ± 2	(8 ± 2) × 10 ³

^a [E] = 0.25 μM, [NS4A Peptide] = 10 μM

5 As can be seen from the forgoing results, all covalent
NS4A-NS3 complexes were shown to have an equivalent catalytic
efficiency to that of full-length NS3₁₋₆₃₁-NS4A₁₋₅₄. In contrast, the non-
covalent complex of NS3₁₋₁₈₁ with the NS4A peptide (0.1:8 μM), KK-
10 (NS4A₂₁₋₃₉)-KK, had an catalytic activity which is 8 fold lower than the
full-length NS3₁₋₆₃₁-NS4A₁₋₅₄.

Example 6

High Throughput Screening Assays Using Covalent NS4A-NS3 Complexes

15 The claimed covalent NS4A-NS3 complexes are useful in
screening methods for identifying NS3 protease inhibitors. One such
method in which the claimed covalent complexes can be used is
illustrated below.

Surface Plasmon Resonance Assay

20 The present example illustrates a method for determining if a
compound can be useful as an HCV protease inhibitor using the surface
plasmon resonance assay. Figures 5A and 5B schematically depict the
25 technique.

20 BIAcore™ is a processing unit for Biospecific Interaction Analysis.
The processing unit integrates an optical detection system with an
30 autosampler and a microfluidic system. BIAcore™ uses the optical

phenomena of surface plasmon resonance to monitor interaction between biomolecules.

SPR is a resonance phenomenon between incoming photons and
5 electrons on the surface of thin metal film. Resonance occurs at a sharply defined angle of incident light. At this angle, called the resonance angle, energy is transferred to the electrons in the metal film, resulting in a decreased intensity of the reflected light. SPR response depends on a change in refractive index in the close vicinity of the sensor chip surface,
10 and is proportional to the mass of analyte bound to the surface. The BIACore™ continuously measures the resonance angle by a relative scale of resonance units (RU) and displays it as an SPR signal in a sensogram, where RU are plotted as a function of time.

15 BIACore™ uses continuous flow technology. One interactant is immobilized irreversibly on the sensor chip, comprising a non-crosslinked carboxymethylated dextran providing a hydrophilic environment for bimolecular interaction. Solution containing the other interactant flows continuously over the sensor chip surface. As
20 molecules from the solution bind to the immobilized ligand, the resonance angle changes resulting in a signal registered by the instrument.

25 In this methodology, the enzymatic reactions are carried out outside of the BIACore™, in reaction tubes or 96-well tissue culture plates, as it is conventionally done for any of the other available high throughput assays. The SPR is only used as a detection means for determination of the amount of an intact substrate remaining in a solution after the reaction is quenched.

30 In order to measure the amount of the intact substrate prior to the addition of enzyme, a means of capturing the substrate onto the sensor chip had to be established. In addition, to satisfy the requirement for a high throughput assay on the BIACore™, the substrate needed to be
35 removed from the surface after completion of analysis, so that the same surface can be used for subsequent reactions. To accomplish these two requirements, a phosphotyrosine is synthetically attached to one end of the substrate. The phosphotyrosine was chosen due to the commercial

- availability of an anti-phosphotyrosine monoclonal antibody. The antibody is covalently attached to the sensor chip by standard amine coupling chemistry. The anti-phosphotyrosine antibody, bound permanently to the chip, is used to capture the phosphotyrosine in a reversible manner. The antibody-phosphotyrosine interaction is ultimately used to capture and release the attached peptide substrate. After completion of analysis, the surface can be regenerated using various reagents such as 2 M MgCl₂.
- When an intact peptide substrate is introduced onto the antibody surface, a large mass is detected by the instrument. To follow the extent of peptide cleavage, a mixture of peptide substrate and enzyme is incubated for the desired time and then quenched. Introduction of this mixture, containing both cleaved peptide and intact peptide, to a regenerated antibody surface results in detection by the instrument of a lower mass than that detected for the sample containing only intact peptide. The difference in the two values is then used to calculate the exact amount of intact peptide remaining after cleavage by the enzyme.
- Although the reduction in mass can be directly followed with many large substrates, due to the small mass of a typical synthetic peptide substrate (10-20 amino acids, 1-3 Daltons), the mass difference, and thus the signal difference between the intact and cleaved peptide, is very small within the signal to noise ratio of the instrument. To circumvent this low sensitivity, a biotin can be attached at the N-terminus of the peptide. Streptavidin can then be added, thus tagging the peptide. When the tagged peptide is introduced onto the antibody surface of the chip, the signal will be higher. The signal resulting from introduction of a cleaved peptide which lacks the N-terminal half, (and thus the streptavidin), will be much lower.

To carry out this method, an HCV protease 5A-5B peptide substrate, (such as 5A/5B substrate DTEDVVACSMSYTWYG-K (SEQ ID NO: 91)) is synthesized with an additional phosphotyrosine at the C-terminus and a biotin at the N-terminus. The biotin is then tagged with streptavidin. An anti-phosphotyrosine monoclonal antibody, 4G10 (Upstate Biotechnology Inc., Lake Placid, New York) is coupled to the sensor chip. In the absence of an active, uninhibited HCV protease,

introduction of the intact phosphotyrosine peptide results in a large signal (large mass unit/large signal) through its interaction with the anti-phosphotyrosine monoclonal antibody (Mab).

- 5 The protease-catalyzed hydrolysis of the phosphotyrosine-biotinylated peptide is carried out in a 96 well plate. The reaction is stopped with an equal volume of mercuribenzoate. The cleaved peptide which lacks the tagged streptavidin (less mass) results in the loss of response units (lower signal).

10

Using this method, numerous compounds can be tested for their inhibitory activity since the antibody surface can be regenerated repetitively with 2 M MgCl₂.

15 Procedure for Coupling Anti-phosphotyrosine Mab to the Sensor Chip

- The anti-phosphotyrosine Mab is coupled to the carboxymethylated dextran surface of a sensor chip in the following manner. The flow rate used throughout the coupling procedure is 5 µl/min. The surface is first activated with a 35 µl injection of NHS/EDC (N-hydroxysuccinimide/N-dimethylaminopropyl-N'-ethylcarbodiimide-HCl). This is followed by a 40 ml injection of Mab 4G10 at 50 µg/ml in 10 mM sodium acetate buffer, pH=4.0. Any remaining activated esters are then blocked by the injection of 35 µl of 1 M ethanolamine. These conditions result in the immobilization of approximately 7,500 response units (420 µM) of antibody.

Binding of Peptide and Regeneration of Mab 4G10 Surface

- 30 The flow rate used throughout the BIACore analysis run is 5 µl/min. A 4 µl injection containing streptavidin-tagged peptide (peptide concentration at 2µM, streptavidin binding sites concentration at 9µM) is carried out. The amount of streptavidin-tagged peptide bound to the antibody surface (in response units) is measured 30 seconds after the injection is complete.

Regeneration of sensor chip surface

Regeneration of the Mab 4G10 surface is achieved using a 4 μ l pulse of 2 M MgCl₂ after each peptide injection. Surfaces regenerated up to 500 times still showed 100% binding of tagged peptide.

5 Determination of the Optimal Concentration of Peptide and Streptavidin

10 To determine the optimal peptide concentration, a standard curve was generated using various amounts of peptide (0-10 μ M) in the presence of excess streptavidin. A value in the linear range, 2 μ M, was chosen for standard assay conditions.

15 The amount of streptavidin required to completely tag the peptide is determined using a peptide concentration of 2.5 μ M and titrating the amount of streptavidin (μ M of binding sites). All the peptides were shown to be completely tagged when streptavidin concentrations greater than 3 μ M (approximately equimolar to the peptide concentration) were used. A streptavidin concentration of 9 μ M (a 4.5 fold excess) was chosen for standard assay conditions.

20

Application of Described Methodology to Covalent HCV NS4A-NS3 Complexes

25 The HCV protease 5A/5B peptide substrate, (such as 5A/5B substrate DTEDVVACSMSYTWYG-K (SEQ ID NO: 91)), with a phosphotyrosine synthetically attached to the C-terminus and a biotin attached at the N-terminus, is synthesized. Anti-phosphotyrosine monoclonal antibody, 4G10 is coupled to the sensor chip.

30

35 In the absence of active, uninhibited covalent HCV NS4A-NS3 complex, the introduction of the intact streptavidin-tagged biotinylated phosphotyrosine peptide to the sensor chip results in a large signal (large mass unit/large response units) through its interaction with the anti-phosphotyrosine monoclonal antibody.

The protease-catalyzed hydrolysis of the phosphotyrosine-biotinylated peptide is carried out with and without a suspected inhibitor

in a 96 well plate. The reaction is stopped with an equal volume of the quenching buffer containing mercuribenzoate. Streptavidin is then added to tag the peptide. The cleaved peptide, which lacks the streptavidin (less mass), results in the loss of response units.

5

Using this assay, numerous compounds can be tested for their inhibitory activity since the antibody surface can be regenerated repetitively with 2 M MgCl₂.

10

Standard Operating Procedure for BIACore-based HCV Assay

15

Reactions are prepared in a 96-well tissue culture plate using the Reaction Buffer (50 mM HEPES, pH 7.4, 20 % glycerol, 150 mM NaCl, 1mM EDTA, 0.1% Tween-20, 1 mM DTT) as diluent. The final reaction volume is 100 µl. Sample with the peptide alone (Biotin-DTEDVVAC SMSYTWTGKpY) is prepared by addition of 10 µl of peptide stock at 100 µM (prepared in the reaction buffer) to 90 µl of reaction buffer, so that the final concentration of peptide is 10 µM. Samples comprised of peptide and the covalent NS4A-NS3 complexes are prepared by addition of 10 µl of peptide stock at 100 µM and 10 µl of covalent NS4A-NS3 stock at 0.17 mg/ml (both prepared in the reaction buffer) to 80 µl of reaction buffer, so that the final concentration of peptide and the enzyme is 10 and 0.1 µM respectively. The reaction is held at 30°C for the specified time and then quenched. Quenching is achieved by transferring a 20-µl aliquot of the reaction mixture to a new tissue culture plate containing an equal volume of PMB Quenching Buffer (50 mM HEPES, pH 7.8, 150 mM NaCl, 5 mM P-Hydroxymercuribenzoic Acid, and 13 mM EDTA).

20

25

30

35

To prepare the quenched reaction mixture for injection onto the sensor surface, 30 µl PMB BIACore Buffer (50 mM HEPES, pH 7.4, 1 M NaCl) and 30 µl of streptavidin at 0.5 mg/ml in water is added to the 40 µl of the quenched reaction mixture to a final volume of 100 µl. In this step, all the peptides are tagged with streptavidin prior to the injection of samples. Finally, 4 µl of this sample is injected over the antiphosphotyrosine surface for determination of the intact versus cleaved peptide. The final concentration of peptide and the streptavidin in the BIACore sample is 2 and 9 µM, respectively.

Experimental Conditions:

	<u>Substrate:</u>	Biotin-DTEDVVAC SMSYTWTGK-pY (SEQ ID NO: 91) in Reaction buffer without DTT
5	<u>Concentration:</u>	170 µM (Crude peptide, based on weight)
10	<u>Enzyme:</u>	10 µl of concentrated His-NS4A ₂₁₋₃₂ -GSGS-NS3 ₃₋₁₈₁ at 0.17 mg/ml
15	<u>Reaction volume:</u>	100 µl 50 mM HEPES, pH 7.8 20 % glycerol 150 mM NaCl 1mM EDTA 1mM DTT 0.1% Tween-20
20	<u>Temp:</u>	30° C
	<u>Quench with:</u>	<i>p</i> -hydroxymercuribenzoate

EXAMPLE 7

Determination of Nucleic Acid Unwinding Activity

The newly engineered single-chain recombinant His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ (SEQ ID NO: 4) was assayed for nucleic acid unwinding activity using a scintillation proximity assay (SPA, Amersham Life Science Inc., Arlington Height, IL). The unwinding activity present in this covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex was compared with that of the full length His-NS3₁₋₆₃₁-NS4A₁₋₅₄ complex under their corresponding optimal buffer conditions. The double stranded RNA substrate (Oligos, Etc., Inc. Wilsonville, OR) used in the assay contained a template 5'-GCU CGC CCG GGG AUC CUC UAG GAA UAC ACG UUC GAU-3' (SEQ ID NO: 121) annealed to a primer 5'-CUA GAG GAU CCC CGG GCG AGC CCU AUA GUG AGU CGU-3' (complementary

sequences of the template and the primer are underlined). This substrate is end-labeled with ^{33}P using T4 polynucleotide kinase.

The assay conditions for the covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex were 100 mM MOPS [pH 7.0], 0.5 mM MgCl₂, 2 mM ATP, 0.5 mM DTT, 100 mg/ml BSA, 2% dimethylsulfoxide (DMSO) and 1 U RNase inhibitor (5 prime->3 prime, Inc., Boulder, CO). For the full length His-NS3₁₋₆₃₁/NS4A₁₋₅₄ complex, the assay conditions were 100 mM PIPES [pH 6.0], 1 mM MgCl₂, 2 mM ATP, 0.6 mM DTT, 100 mg/ml BSA and 1 U RNase inhibitor. In both reactions, 0.5 nM double stranded RNA substrate in a final volume of 50 ml was used. The reaction was carried out at 37 °C for 1 h and terminated by an addition of 10 ml of 0.5 M EDTA. The released primer was captured using 60 ml of 100 nM biotinylated capture oligomer (5'-biotin-GCT-CGC-CCG-GGG-ATC-CTC-TAG-3') (Gibco/BRL, Grand Island, NY) (SEQ ID NO: 123) in 2X hybridization buffer (40 mM HEPES [pH 7.3], 2M NaCl, 2 mg/ml BSA) at 37 °C for 1 h. The primer-oligomer complex was retained by Streptavidin coated SPA beads (SPA, Amersham Life Science Inc., Arlington Height, IL), filtered and washed thoroughly with wash buffer (20 mM HEPES [pH 7.3], 15 mM NaCl, 1.5 mM sodium citrate and 0.05% SDS). The amount of the released labeled primer was quantified using a TopCount reader (Packard A991200, Meriden, CT).

As shown in Fig. 6, the covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ displayed nucleic acid unwinding activity which was proportional to the concentration of enzyme. In the linear range of the assay for both enzymes (1 - 10 pM), about 5 - 6 fold more product was released by the His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ than that from an equivalent concentration of full length His-NS3₁₋₆₃₁/NS4A₁₋₅₄ complex. In addition, 10 fold less covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex was required to yield a similar percentage of unwound products compared with the full length His-NS3₁₋₆₃₁/NS4A₁₋₅₄ complex in the corresponding reactions.

The nucleic acid unwinding activity associated with the recombinant covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex is useful for screening inhibitors of this function. For antiviral screening, compounds were tested at concentrations of less than 40 mM in the assay conditions as described above except that 0.3 nM of the double stranded RNA substrate and 20 pM of the covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex were used in a reaction which was carried out at room temperature for 30 minutes. The inhibition of the enzyme was

monitored by a decrease in the level of released labeled primer as reflected in fewer counts in the capture assay. IC₅₀ of the inhibitory compounds was determined as the concentration of the compounds required to inhibit 50% of the unwinding activity.

5

EXAMPLE 8
Determination of ATPase activity

ATPase activity of the covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex (SEQ ID NO: 4) was monitored by direct measurement of [α-³²P]ATP hydrolysis using thin layer chromatography. The enzyme was incubated with 1 mM ATP mixed with [α-³²P]ATP (3000 Ci/mmol, approximately 0.5 mCi per reaction) in a reaction buffer containing 50 mM HEPES [pH 7.3], 10 mM KCl, 0.5 mM DTT, 100 mg/ml bovine serum albumin, fraction V (BSA), 1 mM MgCl₂ in the presence or absence of 1 mM polyuridylic acid (poly U) (Pharmacia, Piscataway, NJ) in a final volume of 10 ml. The reaction was carried out at 37 °C for 1 h and terminated by an addition of 1 ml of 0.5 M EDTA. Half a microliter of the reaction mix was spotted onto a polyethyleneimine-cellulose sheet (SA Scientific Adsorbents Inc., Atlanta, GA) and developed by ascending chromatography in 0.375 M potassium phosphate buffer [pH 3.5]. The cellulose sheet was dried and quantified with a Storm 860 PhosphoImager (Molecular Dynamics, Sunnyvale, CA).

The covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex exhibited poly U dependent ATPase activity which was proportional to the concentration of the enzyme. The ATP hydrolysis (8 - 13 fold increase) was enhanced in the presence of poly U at all enzyme concentrations examined (see Figure 7). Only minimal ATP hydrolysis was observed in the absence of poly U.

The presence of ATPase activity in this covalent His-NS4A₂₁₋₃₂-GSGS-NS3₃₋₆₃₁ complex makes it suitable for screening inhibitors against HCV helicase.

WE CLAIM:

1. A covalent HCV NS4A-NS3 complex comprising the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the linker to the amino terminus of the HCV NS3 protease domain.
5
2. The covalent HCV NS4A-NS3 complex of claim 1, wherein the linker comprises at least about 4 amino acid residues.
10
3. The covalent HCV NS4A-NS3 complex of claim 2, wherein the linker consists essentially of 4-6 amino acid residues.
15
4. The covalent HCV NS4A-NS3 complex of claim 3, wherein the linker consists essentially of about 4 amino acid residues.
20
5. The covalent HCV NS4A-NS3 complex of claim 4, wherein the linker has a sequence defined by SEQ ID NO: 21 or SEQ ID NO: 22.
25
6. The covalent HCV NS4A-NS3 complex of claim 5, having an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-20.
30
7. The covalent HCV NS4A-NS3 complex of claim 1 which is modified by replacement of one or more hydrophobic amino acid residues at position 17 or 18 of the HCV NS3 serine protease domain with a hydrophilic amino acid residue.
35
8. The covalent HCV NS4A-NS3 complex of claim 7 in which one or more isoleucine residues at position 17 or 18 of the HCV NS3 serine protease domain is replaced by a lysine residue.
9. The covalent HCV NS4A-NS3 complex of claim 8, having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-4, 6-8, 10, 12-14 and 16-18.

10. The covalent HCV NS4A-NS3 complex of claim 1 which is modified by replacement of a serine residue at position 139 of the HCV NS3 serine protease domain with an alanine residue.

5

11. The covalent HCV NS4A-NS3 complex of claim 10, having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-8, 15-18 and 20.

10

12. A nucleic acid encoding a covalent HCV NS4A-NS3 complex, which covalent HCV NS4A-NS3 complex comprises the central hydrophobic domain of native HCV NS4A peptide, a linker, and the HCV NS3 serine protease domain, wherein the hydrophobic domain of native HCV NS4A peptide is tethered by the amino acid linker to the amino terminus of the HCV NS3 protease domain.

15

13. The nucleic acid of claim 12, wherein the linker comprises at least about 4 amino acid residues.

20

14. The nucleic acid of claim 13, wherein the linker consists essentially of 4-6 amino acid residues.

15. The nucleic acid of claim 14, wherein the linker consists essentially of 4 amino acid residues.

25

16. The nucleic acid of claim 15, wherein the amino acid linker has a sequence defined by SEQ ID NO: 21 or SEQ ID NO: 22.

30

17. The nucleic acid of claim 16, which encodes a covalent HCV NS4A-NS3 complex having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20.

35

18. The nucleic acid of claim 12, which encodes a covalent HCV NS4A-NS3 complex which is modified by replacement of one or more hydrophobic amino acid residues at position 17 or 18 of the HCV NS3 serine protease domain with a hydrophilic amino acid residue.

19. The nucleic acid of claim 18 which encodes a covalent HCV NS4A-NS3 complex in which one or more isoleucine residues at position 17 or 18 of the HCV NS3 serine protease domain are replaced by a lysine residue.

5

20. The nucleic acid of claim 19, which encodes a covalent HCV NS4A-NS3 complex having an amino acid sequence selected from the group consisting of SEQ ID NOs: 2-4, 6-8, 10, 12-14 and 16-18.

10

21. The nucleic acid of claim 12, which encodes a covalent HCV NS4A-NS3 complex which is modified by replacement of a serine residue at position 139 of the HCV NS3 serine protease domain with an alanine residue.

15

22. The nucleic acid of claim 21, which encodes a covalent HCV NS4A-NS3 complex having an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-8, 15-18 and 20.

20

23. A recombinant vector comprising the nucleic acid of claim 12, which vector is capable of directing expression of the nucleic acid.

24. A host cell comprising the recombinant vector of claim 23.

25

25. A method for making a covalent HCV NS4A-NS3 complex comprising culturing the host cell of claim 24 under conditions in which the nucleic acid or vector is expressed.

30

26. A method for identifying an HCV NS3 protease inhibitor, comprising (a) contacting a covalent HCV NS4A-NS3 complex of claim 1 with a peptide substrate and a suspected protease inhibitor under conditions in which proteolysis can occur; and (b) detecting whether the covalent HCV NS4-NS3 complex has cleaved the substrate.

35

27. A method for identifying an inhibitor of the nucleic acid unwinding activity of an HCV NS3 helicase, comprising (a) contacting a covalent HCV NS4A-NS3 complex of SEQ ID NO: 4, 12-19 or 20 with a double stranded RNA substrate and a suspected inhibitor under conditions in which unwinding of the substrate can occur; and (b)

detecting whether and the extent to which the covalent HCV NS4-NS3 complex has unwound the substrate.

28. A method for identifying an inhibitor of an HCV NS3 helicase, comprising (a) contacting a covalent HCV NS4A-NS3 complex of SEQ ID NO: 4, 12-19 or 20 with ATP and a suspected inhibitor under conditions in which ATP hydrolysis can occur; and (b) detecting whether the covalent HCV NS4-NS3 complex has exhibited ATPase activity.
- 5

10

15

ABSTRACT OF THE DISCLOSURE

Covalent HCV NS4A-NS3 complexes comprising the
5 central hydrophobic domain of native HCV NS4A peptide, a linker, and
the HCV NS3 serine protease domain, wherein the hydrophobic domain
of native HCV NS4A peptide is tethered by the linker to the amino
terminus of the HCV NS3 protease domain.

10

EEC TRUST U.S. GOVERNMENT OWNED
NOTICE: NOTIFICATION OF GOVERNMENT OWNERSHIP
OF INVENTION

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Malcolm, Bruce
Taremi, Shahriar S.
Weber, Patricia
Yao, Nanhua
- (ii) TITLE OF INVENTION: Covalent Complexes of Hepatitis C Virus NS3 Protease and NS4A Cofactor Peptide
- (iii) NUMBER OF SEQUENCES: 123
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Schering-Plough Corp.
(B) STREET: 2000 Galloping Hill Road
(C) CITY: Kenilworth
(D) STATE: New Jersey
(E) COUNTRY: USA
(F) ZIP: 07030
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: Power Macintosh
(C) OPERATING SYSTEM: 8.0.1
(D) SOFTWARE: Microsoft Word 6.0.1
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US
(B) FILING DATE:
(C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: McLaughlin, Jaye P.
(B) REGISTRATION NUMBER: 41,211
(C) REFERENCE/DOCKET NUMBER: JB0800P2
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (908)298-5056
(B) TELEFAX: (908)298-5388

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 217 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro

1	5	10	15
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu			
20 25 30			
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			
35 40 45			
Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val			
50 55 60			
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala			
65 70 75 80			
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser			
85 90 95			
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn			
100 105 110			
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser			
115 120 125			
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130 135 140			
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser			
145 150 155 160			
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly			
165 170 175			
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180 185 190			
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195 200 205			
Ser Met Glu Thr Thr Met Arg Ser *			
210 215			

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1		5						10				15		
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu														

20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser *		
210	215	

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		

35	40	45
Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
80		
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
160		
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser *		
210	215	

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
15		
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		

50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser *		
210	215	

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 216 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		

65	70	75	80
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser			
85		90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn			
100		105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser			
115	120		125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130	135		140
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser			
145	150	155	160
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly			
165		170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180		185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195	200		205
Ser Met Glu Thr Thr Met Arg Ser			
210	215		

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 216 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1				5				10				15		

Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20				25				30			

Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu
					35			40				45			

Leu	Gly	Cys	Lys	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val
				50			55			60					

Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala
					65		70			75			80		

Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser

85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser		
210	215	

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		

100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser *		
210	215	

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
15		
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
80		
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		

115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser *		
210	215	

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
15		
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Pro Ala Gly Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
80		
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		
100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125

Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg
 130 135 140
 His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser
 145 150 155 160
 Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly
 165 170 175
 Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala
 180 185 190
 Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu
 195 200 205
 Ser Met Glu Thr Thr Met Arg Ser *
 210 215

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 217 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
 1 5 10 15
 Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
 20 25 30
 Ser Pro Ala Gly Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu
 35 40 45
 Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val
 50 55 60
 Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala
 65 70 75 80
 Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser
 85 90 95
 Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn
 100 105 110
 Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser
 115 120 125
 Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg
 130 135 140

His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	
145					150				155				160		
Leu	Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ser	Gly	Gly
					165				170				175		
Pro	Leu	Leu	Cys	Pro	Ser	Gly	His	Ala	Val	Gly	Ile	Phe	Arg	Ala	Ala
					180			185				190			
Val	Cys	Thr	Arg	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Val	Pro	Val	Glut
					195		200					205			
Ser	Met	Glu	Thr	Thr	Met	Arg	Ser	*							
					210		215								

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: protein
 - xii) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met	Gly	Ser	Ser	His	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1				5						10				15	
Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20					25				30		
Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu
				35					40				45		
Leu	Gly	Cys	Ile	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val
				50				55				60			
Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala
				65			70				75				80
Thr	Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser
				85					90					95	
Lys	Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn
				100					105				110		
Val	Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser
				115				120				125			
Leu	Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg
				130				135				140			
His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser
				145			150				155				160

Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly
 165 170 175
 Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala
 180 185 190
 Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu
 195 200 205
 Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser
 210 215 220
 Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro
 225 230 235 240
 Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln
 245 250 255
 Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly
 260 265 270
 Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg
 275 280 285
 Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr
 290 295 300
 Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp
 305 310 315 320
 Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu
 325 330 335
 Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu
 340 345 350
 Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His
 355 360 365
 Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe
 370 375 380
 Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu
 385 390 395 400
 Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu
 405 410 415
 Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430
 Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala
 435 440 445
 Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460
 Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr

465	470	475	480
Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg			
485	490	495	
Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr			
500	505	510	
Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu			
515	520	525	
Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr			
530	535	540	
Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys			
545	550	555	560
Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His			
565	570	575	
Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe			
580	585	590	
Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala			
595	600	605	
Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys			
610	615	620	
Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val			
625	630	635	640
Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala			
645	650	655	
Cys Met Ser Ala Asp Leu Glu Val Val			
660	665		

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro			
1	5	10	15
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu			
20	25	30	
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			

35	40	45	
Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val			
50	55	60	
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala			
65	70	75	80
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser			
85	90	95	
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn			
100	105	110	
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser			
115	120	125	
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130	135	140	
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser			
145	150	155	160
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly			
165	170	175	
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180	185	190	
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195	200	205	
Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser			
210	215	220	
Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro			
225	230	235	240
Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln			
245	250	255	
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly			
260	265	270	
Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg			
275	280	285	
Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr			
290	295	300	
Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp			
305	310	315	320
Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu			
325	330	335	
Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu			
340	345	350	

Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His
 355 360 365

Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe
 370 375 380

Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu
 385 390 395 400

Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu
 405 410 415

Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430

Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala
 435 440 445

Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460

Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr
 465 470 475 480

Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495

Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510

Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525

Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr
 530 535 540

Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560

Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575

Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590

Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala
 595 600 605

Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
 610 615 620

Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
 625 630 635 640

Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

Cys Met Ser Ala Asp Leu Glu Val Val
660 665

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
1 5 10 15

Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
20 25 30

Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu
35 40 45

Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val
50 55 60

Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala
65 70 75 80

Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser
85 90 95

Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn
100 105 110

Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser
115 120 125

Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg
130 135 140

His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser
145 150 155 160

Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly
165 170 175

Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala
180 185 190

Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu
195 200 205

Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser
210 215 220

Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro
 225 230 235 240
 Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln
 245 250 255
 Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly
 260 265 270
 Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg
 275 280 285
 Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr
 290 295 300
 Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp
 305 310 315 320
 Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu
 325 330 335
 Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu
 340 345 350
 Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His
 355 360 365
 Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe
 370 375 380
 Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu
 385 390 395 400
 Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu
 405 410 415
 Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430
 Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala
 435 440 445
 Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460
 Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr
 465 470 475 480
 Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495
 Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510
 Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525
 Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr

530	535	540
Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys		
545	550	555
Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His		
565	570	575
Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe		
580	585	590
Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala		
595	600	605
Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys		
610	615	620
Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val		
625	630	635
Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala		
645	650	655
Cys Met Ser Ala Asp Leu Glu Val Val		
660	665	

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro		
1	5	10
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu		
20	25	30
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu		
35	40	45
Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val		
50	55	60
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala		
65	70	75
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser		
85	90	95
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn		

100	105	110
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser		
115	120	125
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg		
130	135	140
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser		
145	150	155
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly		
165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser		
210	215	220
Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro		
225	230	235
240		
Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln		
245	250	255
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly		
260	265	270
Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg		
275	280	285
Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr		
290	295	300
Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp		
305	310	315
320		
Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu		
325	330	335
Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu		
340	345	350
Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His		
355	360	365
Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe		
370	375	380
Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu		
385	390	395
400		
Ile Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu		
405	410	415

Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430

 Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala
 435 440 445

 Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460

 Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr
 465 470 475 480

 Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495

 Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510

 Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525

 Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr
 530 535 540

 Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560

 Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575

 Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590

 Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala
 595 600 605

 Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
 610 615 620

 Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
 625 630 635 640

 Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

 Cys Met Ser Ala Asp Leu Glu Val Val
 660 665

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Met	Gly	Ser	Ser	His	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro	
1				5						10					15	
Arg	Gly	Ser	His	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
					20					25						30
Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu	
					35				40						45	
Leu	Gly	Cys	Ile	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val	
					50			55				60				
Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala	
					65			70			75				80	
Thr	Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser	
					85				90						95	
Lys	Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn	
					100				105						110	
Val	Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser	
					115			120				125				
Leu	Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg	
					130			135				140				
His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	
					145			150			155				160	
Leu	Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ala	Gly	Gly	
					165				170						175	
Pro	Leu	Leu	Cys	Pro	Ser	Gly	His	Ala	Val	Gly	Ile	Phe	Arg	Ala	Ala	
					180				185						190	
Val	Cys	Thr	Arg	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Val	Pro	Val	Glu	
					195				200						205	
Ser	Met	Glu	Thr	Thr	Met	Arg	Ser	Pro	Val	Phe	Thr	Asp	Asn	Ser	Ser	
					210			215			220					
Pro	Pro	Ala	Val	Pro	Gln	Ser	Phe	Gln	Val	Ala	His	Leu	His	Ala	Pro	
					225			230			235				240	
Thr	Gly	Ser	Gly	Lys	Ser	Thr	Lys	Val	Pro	Ala	Ala	Tyr	Ala	Ala	Gln	
					245				250						255	
Gly	Tyr	Lys	Val	Leu	Val	Leu	Asn	Pro	Ser	Val	Ala	Ala	Thr	Leu	Gly	
					260				265						270	
Phe	Gly	Ala	Tyr	Met	Ser	Lys	Ala	His	Gly	Ile	Asp	Pro	Asn	Ile	Arg	
					275				280						285	

Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr
 290 295 300
 Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp
 305 310 315 320
 Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu
 325 330 335
 Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu
 340 345 350
 Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His
 355 360 365
 Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe
 370 375 380
 Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Arg His Leu
 385 390 395 400
 Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu
 405 410 415
 Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430
 Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala
 435 440 445
 Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460
 Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr
 465 470 475 480
 Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495
 Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510
 Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525
 Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr
 530 535 540
 Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560
 Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575
 Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590
 Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala

595	600	605
Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys		
610	615	620
Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val		
625	630	635 640
Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala		
645	650	655
Cys Met Ser Ala Asp Leu Glu Val Val		
660	665	

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro	
1				5					10				15		
Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20					25				30		
Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu
				35					40				45		
Leu	Gly	Cys	Lys	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val
				50					55				60		
Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala
				65					70				75		80
Thr	Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser
				85					90				95		
Lys	Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn
				100					105				110		
Val	Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser
				115					120				125		
Leu	Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg
				130					135				140		
His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	
				145					150				155		160
Leu	Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ala	Gly	Gly

165	170	175
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala		
180	185	190
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu		
195	200	205
Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser		
210	215	220
Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro		
225	230	235
Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln		
245	250	255
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly		
260	265	270
Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg		
275	280	285
Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr		
290	295	300
Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp		
305	310	315
Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu		
325	330	335
Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu		
340	345	350
Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His		
355	360	365
Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe		
370	375	380
Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu		
385	390	395
Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu		
405	410	415
Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val		
420	425	430
Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala		
435	440	445
Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn		
450	455	460
Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr		
465	470	475
480		

Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495

Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510

Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525

Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr
 530 535 540

Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560

Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575

Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590

Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala
 595 600 605

Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
 610 615 620

Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
 625 630 635 640

Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

Cys Met Ser Ala Asp Leu Glu Val Val
 660 665

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
 1 5 10 15

Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
 20 25 30

Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu
 35 40 45

Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val
 50 55 60

Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala
 65 70 75 80

Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser
 85 90 95

Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn
 100 105 110

Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser
 115 120 125

Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg
 130 135 140

His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser
 145 150 155 160

Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly
 165 170 175

Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala
 180 185 190

Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu
 195 200 205

Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser
 210 215 220

Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro
 225 230 235 240

Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln
 245 250 255

Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly
 260 265 270

Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg
 275 280 285

Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr
 290 295 300

Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Ala Tyr Asp
 305 310 315 320

Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu
 325 330 335

Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu
 340 345 350

Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His
 355 360 365

Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe
 370 375 380

Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu
 385 390 395 400

Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu
 405 410 415

Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val
 420 425 430

Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala
 435 440 445

Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn
 450 455 460

Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr
 465 470 475 480

Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg
 485 490 495

Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr
 500 505 510

Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu
 515 520 525

Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr
 530 535 540

Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560

Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575

Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590

Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala
 595 600 605

Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
 610 615 620

Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
 625 630 635 640

Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

Cys Met Ser Ala Asp Leu Glu Val Val

660

665

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 665 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro	
1				5				10				15			
Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20				25				30			
Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu
				35				40				45			
Leu	Gly	Cys	Lys	Lys	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val
				50			55				60				
Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala
				65			70			75			80		
Thr	Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser
				85				90				95			
Lys	Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn
				100				105				110			
Val	Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser
				115				120				125			
Leu	Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg
				130			135				140				
His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser
				145			150			155			160		
Leu	Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ala	Gly	Gly
				165				170				175			
Pro	Leu	Leu	Cys	Pro	Ser	Gly	His	Ala	Val	Gly	Ile	Phe	Arg	Ala	Ala
				180				185				190			
Val	Cys	Thr	Arg	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Val	Pro	Val	Glù
				195				200				205			
Ser	Met	Glu	Thr	Thr	Met	Arg	Ser	Pro	Val	Phe	Thr	Asp	Asn	Ser	Ser
				210			215				220				
Pro	Pro	Ala	Val	Pro	Gln	Ser	Phe	Gln	Val	Ala	His	Leu	His	Ala	Pro

225	230	235	240
Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln			
245		250	255
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly			
260	265	270	
Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg			
275	280	285	
Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr			
290	295	300	
Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp			
305	310	315	320
Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu			
325	330	335	
Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu			
340	345	350	
Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His			
355	360	365	
Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe			
370	375	380	
Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu			
385	390	395	400
Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu			
405	410	415	
Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val			
420	425	430	
Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala			
435	440	445	
Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn			
450	455	460	
Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr			
465	470	475	480
Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg			
485	490	495	
Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr			
500	505	510	
Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu			
515	520	525	
Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr			
530	535	540	

Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys
 545 550 555 560
 Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His
 565 570 575
 Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe
 580 585 590
 Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala
 595 600 605
 Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys
 610 615 620
 Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val
 625 630 635 640
 Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655
 Cys Met Ser Ala Asp Leu Glu Val Val
 660 665

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 671 amino acids
 - (B) TYPE: amino acid
 - (C) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
 1 5 10 15
 Arg Gly Ser His Met Ala Tyr Ser Leu Thr Thr Gly Ser Val Val Ile
 20 25 30
 Val Gly Arg Ile Ile Leu Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser
 35 40 45
 Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly
 50 55 60
 Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr Ala
 65 70 75 80
 Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr Val
 85 90 95
 Tyr His Gly Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile
 100 105 110

Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln Ala
 115 120 125

Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp
 130 135 140

Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg
 145 150 155 160

Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu
 165 170 175

Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala Val
 180 185 190

Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val
 195 200 205

Asp Phe Val Pro Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro Val
 210 215 220

Phe Thr Asp Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val
 225 230 235 240

Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro
 245 250 255

Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser
 260 265 270

Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly
 275 280 285

Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ala
 290 295 300

Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys
 305 310 315 320

Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr
 325 330 335

Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu
 340 345 350

Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly
 355 360 365

Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Asn
 370 375 380

Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile
 385 390 395 400

Arg Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp
 405 410 415

Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr
 420 425 430

Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ile Gly Asp Val Val
 435 440 445

Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp
 450 455 460

Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser
 465 470 475 480

Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Thr Val Pro Gln Asp Ala
 485 490 495

Val Ser Arg Ser Gln Arg Arg Gly Arg Thr Gly Arg Gly Arg Gly
 500 505 510

Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg Pro Ser Gly Met Phe Asp
 515 520 525

Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu
 530 535 540

Leu Thr Pro Ala Glu Thr Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr
 545 550 555 560

Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Ser Val
 565 570 575

Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys
 580 585 590

Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val
 595 600 605

Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys
 610 615 620

Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu
 625 630 635 640

Tyr Arg Leu Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile
 645 650 655

Thr Lys Tyr Ile Met Ala Cys Met Ser Ala Asp Leu Glu Val Val
 660 665 670

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 671 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Met	Gly	Ser	Ser	His	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1				5				10					15		
Arg	Gly	Ser	His	Met	Ala	Tyr	Ser	Leu	Thr	Thr	Gly	Ser	Val	Val	Ile
				20				25					30		
Val	Gly	Arg	Ile	Ile	Leu	Ser	Gly	Ser	Gly	Ser	Ile	Thr	Ala	Tyr	Ser
				35			40				45				
Gln	Gln	Thr	Arg	Gly	Leu	Leu	Gly	Ile	Ile	Thr	Ser	Leu	Thr	Gly	
				50			55			60					
Arg	Asp	Lys	Asn	Gln	Val	Glu	Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala
				65			70			75			80		
Thr	Gln	Ser	Phe	Leu	Ala	Thr	Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val
				85				90				95			
Tyr	His	Gly	Ala	Gly	Ser	Lys	Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile
				100				105				110			
Thr	Gln	Met	Tyr	Thr	Asn	Val	Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala
				115			120				125				
Pro	Pro	Gly	Ala	Arg	Ser	Leu	Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp
				130			135			140					
Leu	Tyr	Leu	Val	Thr	Arg	His	Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Arg
				145			150			155			160		
Gly	Asp	Ser	Arg	Gly	Ser	Leu	Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu
				165				170				175			
Lys	Gly	Ser	Ala	Gly	Gly	Pro	Leu	Leu	Cys	Pro	Ser	Gly	His	Ala	Val
				180			185				190				
Gly	Ile	Phe	Arg	Ala	Ala	Val	Cys	Thr	Arg	Gly	Val	Ala	Lys	Ala	Val
				195			200			205					
Asp	Phe	Val	Pro	Val	Glu	Ser	Met	Glu	Thr	Thr	Met	Arg	Ser	Pro	Val
				210			215			220					
Phe	Thr	Asp	Asn	Ser	Ser	Pro	Pro	Ala	Val	Pro	Gln	Ser	Phe	Gln	Val
				225			230			235			240		
Ala	His	Leu	His	Ala	Pro	Thr	Gly	Ser	Gly	Lys	Ser	Thr	Lys	Val	Pro
				245				250				255			
Ala	Ala	Tyr	Ala	Ala	Gln	Gly	Tyr	Lys	Val	Leu	Val	Leu	Asn	Pro	Ser
				260			265				270				
Val	Ala	Ala	Thr	Leu	Gly	Phe	Gly	Ala	Tyr	Met	Ser	Lys	Ala	His	Gly
				275			280				285				
Ile	Asp	Pro	Asn	Ile	Arg	Thr	Gly	Val	Arg	Thr	Ile	Thr	Thr	Gly	Ala

290	295	300
Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys		
305	310	315
Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys Asp Glu Cys His Ser Thr		
325	330	335
Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu		
340	345	350
Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly		
355	360	365
Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Asn		
370	375	380
Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile		
385	390	395
Arg Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Cys Asp		
405	410	415
Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr		
420	425	430
Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ile Gly Asp Val Val		
435	440	445
Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp		
450	455	460
Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser		
465	470	475
Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Thr Val Pro Gln Asp Ala		
485	490	495
Val Ser Arg Ser Gln Arg Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly		
500	505	510
Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg Pro Ser Gly Met Phe Asp		
515	520	525
Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu		
530	535	540
Leu Thr Pro Ala Glu Thr Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr		
545	550	555
Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Ser Val		
565	570	575
Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys		
580	585	590
Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val		
595	600	605

Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys
 610 615 620

Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu
 625 630 635 640

Tyr Arg Leu Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile
 645 650 655

Thr Lys Tyr Ile Met Ala Cys Met Ser Ala Asp Leu Glu Val Val
 660 665 670

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Gly Ser Gly Ser
 1

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Pro Ala Gly Gly
 1

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1964 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..1964

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 632 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Met Ala Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly
1 5 10 15

Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly
20 25 30

Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys
35 40 45

Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr
50 55 60

Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp
65 70 75 80

Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr
85 90 95

Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala
 100 105 110

Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu
115 120 125

Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu
120 125 130

Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys
145 150 155 160

Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met
165 170 175

Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro
123 134 135 136 137 138 139

Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly
105 200 300

Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr
 210 215 220

 Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly
 225 230 235 240

 Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly
 245 250 255

 Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly
 260 265 270

 Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile
 275 280 285

 Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile
 290 295 300

 Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val
 305 310 315 320

 Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn
 325 330 335

 Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly
 340 345 350

 Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe
 355 360 365

 Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly
 370 375 380

 Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val
 385 390 395 400

 Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met
 405 410 415

 Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys
 420 425 430

 Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu
 435 440 445

 Thr Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly
 450 455 460

 Arg Thr Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly
 465 470 475 480

 Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr
 485 490 495

 Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val
 500 505 510

Arg	Leu	Arg	Ala	Tyr	Leu	Asn	Thr	Pro	Gly	Leu	Pro	Val	Cys	Gln	Asp
515														525	
His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp															
530 535 540															
Ala	His	Phe	Leu	Ser	Gln	Thr	Lys	Gln	Ala	Gly	Asp	Asn	Phe	Pro	Tyr
545												555			560
Leu	Val	Ala	Tyr	Gln	Ala	Thr	Val	Cys	Ala	Arg	Ala	Gln	Ala	Pro	Pro
565												570			575
Pro	Ser	Trp	Asp	Gln	Met	Trp	Lys	Cys	Leu	Ile	Arg	Leu	Lys	Pro	Thr
580												585			590
Leu	His	Gly	Pro	Thr	Pro	Leu	Leu	Tyr	Arg	Leu	Gly	Ala	Val	Gln	Asn
595												600			605
Glu	Val	Thr	Leu	Thr	His	Pro	Ile	Thr	Lys	Tyr	Ile	Met	Ala	Cys	Met
610												615			620
Ser	Ala	Asp	Leu	Glu	Val	Val	Val	Thr							
625												630			

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 54 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Ser	Thr	Trp	Val	Leu	Val	Gly	Gly	Val	Leu	Ala	Ala	Leu	Ala	Ala	Tyr
1															15
Cys Leu Thr Thr Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu Ser															
20 25 30															
Gly	Arg	Pro	Ala	Ile	Val	Pro	Asp	Arg	Glu	Leu	Leu	Tyr	Gln	Glu	Phe
35												40		45	
Asp	Glu	Met	Glu	Glu	Cys										
50															

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Asp	Thr	Glu	Asp	Val	Val	Cys	Cys	Ser	Met	Tyr	Thr	Trp	Thr	Gly	Lys
1				5					10				15		

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 78 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

GATATACATA	TGGGTTCTGT	TGTTATTGTT	GGTAGAATTA	TTTTATCTGG	TAGTGGTAGT	60
ATCACGGCCT	ACTCCCAA					78

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CTCAGCGAAT	TCTCAAGACC	GCATAGTAGT	TTCCCAT	36
------------	------------	------------	---------	----

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CGGGGCCTAC TTGGTTGCAT CAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CGGGGCCTAC TTGGTTGCAA GAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 39 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

GCCTGTAAAGG CTAGTCTTCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CTCCTACTTG AAGGGCTCTG CTGGTGGTCC ACTGCTCTGC

40

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GCAGAGCAGT GGACCACCAAG CAGAGCCCTT CAAGTAGGAG

40

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CGGGGCCTAC TTGGTTGCAT CAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CGGGGCCTAC TTGGTTGCAA GAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 78 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

GATATACATA TGGGTTCTGT TGTTATTGTT GGTAGAATTA TTTTATCTCC TGCTGGTGTT	60
ATCACGGCCT ACTCCCAA	78

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 36 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

CTCAGCGAAT TCTCAAGACC GCATAGTAGT TTCCAT	36
---	----

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC	39
--	----

(2) INFORMATION FOR SEQ ID NO:45:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 216 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
1 5 10 15

Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
20 25 30

Ser Pro Ala Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu
35 40 45

Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu
50 55 60

Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr
65 70 75 80

Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys
85 90 95

Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val
100 105 110

Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu
115 120 125

Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His
130 135 140

Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu
145 150 155 160

Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro
165 170 175

Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val
180 185 190

Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser
 195 200 205

Met Glu Thr Thr Met Arg Ser *
210 215

(2) INFORMATION FOR SEQ ID NO:47:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - ii) MOLECULE TYPE: peptide

Pro Ala Gly

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 75 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

GATATACATA TGGGTTCTGT TGTATTGTT GGTAGAATT A TTTTATCTCC TGCTCCATG 60

ACGGCCCTACT CCCAA

(2) INFORMATION FOR SEQ ID NO:48:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(11) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

CTCAGCGAAT TCTCAAGACC GCATAGTAGT TTCCAT

36

(2) INFORMATION FOR SEQ ID NO:50:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 213 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro	
1				5					10			15			
Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20					25			30			
Ser	Pro	Ala	Gly	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu	Leu
				35				40			45				
Gly	Cys	Lys	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val	Glu
				50			55			60					
Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala	Thr
	65				70				75			80			
Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser	Lys
				85				90			95				
Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn	Val
				100				105			110				
Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser	Leu
				115			120				125				
Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg	His
				130			135			140					
Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	Leu	
				145			150			155			160		
Leu	Ser	Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ser	Gly	Gly	Pro
				165				170			175				
Leu	Leu	Cys	Pro	Ser	Gly	His	Ala	Val	Gly	Ile	Phe	Arg	Ala	Ala	Val
				180				185			190				
Cys	Thr	Arg	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Val	Pro	Val	Glu	Ser
				195				200			205				
Met	Glu	Thr	Thr	Met											
				210											

(2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

CGGGGGCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

GCCTGTAAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 166 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Met Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu
 1 5 10 15

Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val
 20 25 30

Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu
 35 40 45

Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln
 50 55 60

Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser	Leu	Thr	Pro
65															80
Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg	His	Ala	Asp
				85						90					95
Val	Ile	Pro	Val	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	Leu	Leu	Ser	
				100				105				110			
Pro	Arg	Pro	Val	Ser	Tyr	Leu	Lys	Gly	Ser	Ser	Gly	Gly	Pro	Leu	Leu
					115			120					125		
Cys	Pro	Ser	Gly	His	Ala	Val	Gly	Ile	Phe	Arg	Ala	Ala	Val	Cys	Thr
				130			135					140			
Arg	Gly	Val	Ala	Lys	Ala	Val	Asp	Phe	Val	Pro	Val	Glu	Ser	Met	Glu
				145			150			155			160		
Thr	Thr	Met	Arg	Ser	*										
				165											

(2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 3 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Gly Gly Ser
1

(2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 75 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

GATATACATA TGGGTTCTGT TGTTATTGTT GGTAGAATTA TTTTATCTGG TGGTTCTATC	60
ACGGCCTACT CCCAA	75

(2) INFORMATION FOR SEQ ID NO:56:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

CTCAGCGAAT TCTCAAGACC GCATAGTAGT TTCCAT

36

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 216 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Met	Gly	Ser	Ser	His	His	His	His	His	Ser	Ser	Gly	Leu	Val	Pro
1				5					10				15	

Arg	Gly	Ser	His	Met	Gly	Ser	Val	Val	Ile	Val	Gly	Arg	Ile	Ile	Leu
				20				25					30		

Ser	Gly	Gly	Ser	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu	Leu
				35				40			45				

Gly	Cys	Lys	Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val	Glu
			50			55				60					

Gly	Glu	Val	Gln	Val	Val	Ser	Thr	Ala	Thr	Gln	Ser	Phe	Leu	Ala	Thr
			65		70			75		80					

Cys	Val	Asn	Gly	Val	Cys	Trp	Thr	Val	Tyr	His	Gly	Ala	Gly	Ser	Lys
				85				90		95					

Thr	Leu	Ala	Gly	Pro	Lys	Gly	Pro	Ile	Thr	Gln	Met	Tyr	Thr	Asn	Val
				100				105			110				

Asp	Gln	Asp	Leu	Val	Gly	Trp	Gln	Ala	Pro	Pro	Gly	Ala	Arg	Ser	Leu
			115			120			125						

Thr	Pro	Cys	Thr	Cys	Gly	Ser	Ser	Asp	Leu	Tyr	Leu	Val	Thr	Arg	His
			130			135			140						

Ala	Asp	Val	Ile	Pro	Val	Arg	Arg	Gly	Asp	Ser	Arg	Gly	Ser	Leu	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--

145	150	155	160
Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro			
165		170	175
Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val			
180		185	190
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser			
195		200	205
Met Glu Thr Thr Met Arg Ser *			
210		215	

(2) INFORMATION FOR SEQ ID NO:58:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:60:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 668 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Met His Met His His His His His His Leu Val Pro Arg Gly Ser Ala
 1 5 10 15

Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Lys
 20 25 30

Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val
 35 40 45

Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn
 50 55 60

Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala
 65 70 75 80

Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp
 85 90 95

Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys
 100 105 110

Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val
 115 120 125

Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro
 130 135 140

Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys
 145 150 155 160

Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg
 165 170 175

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr
 180 185 190

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val
 195 200 205

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly
 210 215 220

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val
 225 230 235 240

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr
 245 250 255

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg
 260 265 270

Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe
 275 280 285

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys
 290 295 300

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr

305	310	315	320
Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala			
325	330	335	
Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu			
340	345	350	
Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala			
355	360	365	
Ile Pro Ile Glu Ala Ile Arg Gly Arg His Leu Ile Phe Cys His			
370	375	380	
Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly			
385	390	395	400
Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro			
405	410	415	
Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly			
420	425	430	
Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr			
435	440	445	
Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr			
450	455	460	
Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr			
465	470	475	480
Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg			
485	490	495	
Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala			
500	505	510	
Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu			
515	520	525	
Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu			
530	535	540	
Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His			
545	550	555	560
Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val			
565	570	575	
Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser			
580	585	590	
Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His			
595	600	605	
Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val			
610	615	620	

Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala
 625 630 635 640

Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys
 645 650 655

Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg
 660 665

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 668 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Met His Met His His His His His Leu Val Pro Arg Gly Ser Ala

1	5	10	15
Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile			
20		25	30
Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val			
35	40		45
Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn			
50	55		60
Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala			
65	70	75	80
Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp			
85		90	95
Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys			
100		105	110
Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val			
115	120		125
Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro			
130	135		140
Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys			
145	150	155	160
Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg			
165		170	175
Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr			
180	185		190
Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val			
195	200		205
Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly			
210	215		220
Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val			
225	230	235	240
Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr			
245	250		255
Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg			
260	265		270
Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe			
275	280		285
Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys			
290	295		300
Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr			
305	310	315	320

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala
 325 330 335

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu
 340 345 350

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala
 355 360 365

Ile Pro Ile Glu Ala Ile Arg Gly Arg His Leu Ile Phe Cys His
 370 375 380

Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly
 385 390 395 400

Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro
 405 410 415

Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly
 420 425 430

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr
 435 440 445

Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr
 450 455 460

Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr
 465 470 475 480

Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg
 485 490 495

Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala
 500 505 510

Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu
 515 520 525

Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu
 530 535 540

Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His
 545 550 555 560

Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val
 565 570 575

Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser
 580 585 590

Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His
 595 600 605

Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val
 610 615 620

Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala
 625 630 635 640

Asp Leu Glu Val Val Thr *

(2) INFORMATION FOR SEQ ID NO:64:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

CGGGGCCTAC TTGGTTGCAT CAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:65:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:66:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 668 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Met His Met His His His His His Leu Val Pro Arg Gly Ser Ala
 1 5 10 15

Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile
 20 25 30

Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val
 35 40 45

Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn
 50 55 60

Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala
 65 70 75 80

Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp
 85 90 95

Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys
 100 105 110

Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val
 115 120 125

Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro
 130 135 140

Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly Pro Leu Leu Cys
 145 150 155 160

Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg
 165 170 175

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr
 180 185 190

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val
 195 200 205

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly
 210 215 220

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val
 225 230 235 240

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr
 245 250 255

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg
 260 265 270

Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe
 275 280 285

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys
 290 295 300

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr
 305 310 315 320

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala
 325 330 335

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu
 340 345 350
 Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala
 355 360 365
 Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His
 370 375 380
 Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly
 385 390 395 400
 Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro
 405 410 415
 Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly
 420 425 430
 Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr
 435 440 445
 Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr
 450 455 460
 Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr
 465 470 475 480
 Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg
 485 490 495
 Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala
 500 505 510
 Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu
 515 520 525
 Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu
 530 535 540
 Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His
 545 550 555 560
 Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val
 565 570 575
 Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser
 580 585 590
 Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His
 595 600 605
 Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val
 610 615 620
 Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala
 625 630 635 640
 Asp Leu Glu Val Val Thr *

(2) INFORMATION FOR SEQ ID NO:67:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

CTCCTACTTG AAGGGCTCTG CTGGTGGTCC ACTGCTCTGC

40

(2) INFORMATION FOR SEQ ID NO:68:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 40 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

GCAGAGCAGT GGACCACCAAG CAGAGCCCTT CAAGTAGGAG

40

(2) INFORMATION FOR SEQ ID NO:69:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 668 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Met	His	Met	His	His	His	His	His	Leu	Val	Pro	Arg	Gly	Ser	Ala
1								10						15

Pro	Ile	Thr	Ala	Tyr	Ser	Gln	Gln	Thr	Arg	Gly	Leu	Leu	Gly	Cys	Ile
								25						30	

Ile	Thr	Ser	Leu	Thr	Gly	Arg	Asp	Lys	Asn	Gln	Val	Glu	Gly	Glu	Val
								35	40					45	

Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn
 50 55 60

Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala
 65 70 75 80

Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp
 85 90 95

Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys
 100 105 110

Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val
 115 120 125

Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro
 130 135 140

Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys
 145 150 155 160

Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg
 165 170 175

Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr
 180 185 190

Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val
 195 200 205

Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly
 210 215 220

Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val
 225 230 235 240

Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr
 245 250 255

Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg
 260 265 270

Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe
 275 280 285

Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys
 290 295 300

Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr
 305 310 315 320

Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala
 325 330 335

Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu
 340 345 350

Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala

355	360	365
Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His		
370	375	380
Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly		
385	390	395
Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro		
405	410	415
Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly		
420	425	430
Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr		
435	440	445
Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr		
450	455	460
Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr		
465	470	475
Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg		
485	490	495
Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala		
500	505	510
Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu		
515	520	525
Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu		
530	535	540
Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His		
545	550	555
Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val		
565	570	575
Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser		
580	585	590
Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His		
595	600	605
Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val		
610	615	620
Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala		
625	630	635
Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys		
645	650	655
Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg		
660	665	

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

GTCCGTCATA CCAACTTCCG GAGACGTCGT TGTCT

35

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

CGACAAACGAC GTCTCCGGAA GTTGGTATGA CGGAC

35

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 669 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Met His Met His His His His His Leu Val Pro Arg Gly Ser Ala
 1 5 10 15

Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile
 20 25 30

Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val
 35 40 45

Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn

50	55	60
Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala		
65	70	75
Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp		
85	90	95
Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys		
100	105	110
Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val		
115	120	125
Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro		
130	135	140
Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys		
145	150	155
Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg		
165	170	175
Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr		
180	185	190
Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val		
195	200	205
Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly		
210	215	220
Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val		
225	230	235
Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr		
245	250	255
Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg		
260	265	270
Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe		
275	280	285
Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys		
290	295	300
Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr		
305	310	315
Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala		
325	330	335
Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu		
340	345	350
Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala		
355	360	365

Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His
 370 375 380
 Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly
 385 390 395 400
 Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro
 405 410 415
 Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly
 420 425 430
 Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr
 435 440 445
 Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr
 450 455 460
 Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr
 465 470 475 480
 Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg
 485 490 495
 Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala
 500 505 510
 Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu
 515 520 525
 Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu
 530 535 540
 Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His
 545 550 555 560
 Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val
 565 570 575
 Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser
 580 585 590
 Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His
 595 600 605
 Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val
 610 615 620
 Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala
 625 630 635 640
 Asp Leu Glu Val Val Thr *

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

ACTAAAGTGC CGGCTGCCTA CGCAGCCCAA GGG

33

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

CCCTTGGGCT GCGTAGGCAG CCGGCACCTTT AGT

33

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

CGGGGCCTAC TTGGTTGCAT CAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 38 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

CGGGGCCTAC TTGGTTGCAA GAAGACTAGC CTTACAGG

38

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

GCCTGTAAGG CTAGTCTTCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:81:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

CGGGGCCTAC TTGGTTGCAA GATCACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

GCCTGTAAGG CTAGTGATCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

CGGGGCCTAC TTGGTTGCAT CAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

GCCTGTAAGG CTAGTCTTGA TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

CGGGGCCTAC TTGGTTGCAA GAAGACTAGC CTTACAGGC

39

(2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

GCCTGTAAGG CTAGTCTTCT TGCAACCAAG TAGGCCCG

39

(2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 96 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

GATATACATA TGGCTTACTC TCTGACTACG GGTTCTGTG TTATTGTTGG TAGAATTATT

60

TTATCTGGTA GTGGTAGTAT CACGGCCTAC TCCCAA

96

(2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

GTGGTGGTGC TCGAGGCTGC CGCGCGGCAC CAGCGTAACG ACCTCCAGGT C

51

(2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 96 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

GATATACATA TGGCTTACTC TCTGACTACG GGTTCTGTG TTATTGTTGG TAGAATTATT

60

TTATCTGGTA GTGGTAGTAT CACGGCCTAC TCCCAA

96

(2) INFORMATION FOR SEQ ID NO:90:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 50 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

TGGTGGTGCT CGAGGCTGCC GCGCGGCACC AGCGTAACGA CCTCCAGGTC

50

(2) INFORMATION FOR SEQ ID NO:91:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Asp Thr Glu Asp Val Val Ala Cys Ser Met Ser Tyr Thr Trp Tyr Gly
1 5 10 15

Lys

(2) INFORMATION FOR SEQ ID NO:92:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 651 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro

48

1	5	10	15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	20	25	30	96
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	35	40	45	144
CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	50	55	60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	65	70	75	80
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA- Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	85	90	95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	100	105	110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	115	120	125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	130	135	140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	145	150	155	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly	165	170	175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala	180	185	190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu	195	200	205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser *	210	215		651

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 651 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	48
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	96
20 25 30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	144
35 40 45	
CTT GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	192
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	240
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	288
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	336
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	384
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	432
130 135 140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser	480
145 150 155 160	
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly	528
165 170 175	

CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser * 210 215	651

(2) INFORMATION FOR SEQ ID NO:94:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 651 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15	48
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu 35 40 45	144
CTT GGT TGC ATC AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val 50 55 60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336

GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser * 210 215	651

(2) INFORMATION FOR SEQ ID NO:95:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 651 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15	48
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA	144

Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			
35	40	45	
CTT GGT TGC AAG AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC			192
Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val			
50	55	60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG			240
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala			
65	70	75	80
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA			288
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser			
85	90	95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT			336
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn			
100	105	110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC			384
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser			
115	120	125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA			432
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130	135	140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC			480
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser			
145	150	155	160
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT			528
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly			
165	170	175	
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC			576
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180	185	190	
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG			624
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195	200	205	
TCC ATG GAA ACT ACT ATG CGG TCT TGA			651
Ser Met Glu Thr Thr Met Arg Ser *			
210	215		

(2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 650 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..650

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro	48
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	96
20 25 30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	144
35 40 45	
CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	192
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	240
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	288
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	336
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	384
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	432
130 135 140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	480
145 150 155 160	
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly	528
165 170 175	
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala	576
180 185 190	
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu	624

195	200	205	
TCC ATG GAA ACT ACT ATG CGG TCT TG			650
Ser Met Glu Thr Thr Met Arg Ser			
210	215		

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 650 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..650

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG	48
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro	
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT ATT TTA	96
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	
20 25 30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA	144
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	
35 40 45	
CTT GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC	192
Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG	240
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA	288
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT	336
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC	384
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA	432

Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130	135	140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC			480
His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser			
145	150	155	160
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT			528
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly			
165	170	175	
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC			576
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180	185	190	
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG			624
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195	200	205	
TCC ATG GAA ACT ACT ATG CGG TCT TG			650
Ser Met Glu Thr Thr Met Arg Ser			
210	215		

(2) INFORMATION FOR SEQ ID NO:98:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 651 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG			48
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro			
1	5	10	15
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA			96
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu			
20	25	30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA			144
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			
35	40	45	
CTT GGT TGC ATC AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC			192
Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val			
50	55	60	

GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser * 210 215	651

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 651 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..651

(2) INFORMATION FOR SEQ ID NO:100:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 651 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG-	48
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA	96
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	
20 25 30	
TCT CCT GCT GGT GGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA	144
Ser Pro Ala Gly Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	
35 40 45	
CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC	192
Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG	240
Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA	288
Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT	336
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC	384
Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA	432
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	
130 135 140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC	480
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	
145 150 155 160	

CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser * 210 215	651

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 651 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..651

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15	48
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT CCT GCT GGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Pro Ala Gly Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu 35 40 45	144
CTT GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val 50 55 60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	288

	85	90	95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	100	105	110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	115	120	125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	130	135	140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	145	150	155	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly	165	170	175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala	180	185	190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu	195	200	205	624
TCC ATG GAA ACT ACT ATG CGG TCT TGA Ser Met Glu Thr Thr Met Arg Ser *	210	215		651

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
- (A) NAME/KEY: CDS
 - (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro	1	5	10	48
			15	

CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu 35 40 45	144
CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val 50 55 60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GGC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln	768

	245	250	255	
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly	260	265	270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg	275	280	285	864
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr	290	295	300	912
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp	305	310	315	960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu	325	330	335	1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu	340	345	350	1056
GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His	355	360	365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe	370	375	380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu	385	390	395	1200
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu	405	410	415	1248
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val	420	425	430	1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala	435	440	445	1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn	450	455	460	1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr	465	470	475	1440

ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg 485	490	495	1488	
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr 500	505	510	1536	
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515	520	525	1584	
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530	535	540	1632	
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545	550	555	560	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565	570	575	1728	
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe 580	585	590	1776	
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala 595	600	605	1824	
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys 610	615	620	1872	
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val 625	630	635	640	1920
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala 645	650	655	1968	
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT Cys Met Ser Ala Asp Leu Glu Val Val 660	665		1998	

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1997

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	48
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	96
20 25 30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	144
35 40 45	
CTT GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	192
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	240
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	288
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	336
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	384
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	432
130 135 140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser	480
145 150 155 160	
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly	528
165 170 175	

CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln 245 250 255	768
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly 260 265 270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg 275 280 285	864
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr 290 295 300	912
TAT GGC AAG TTT CTT GCC GAT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Ala Tyr Asp 305 310 315 320	960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu 325 330 335	1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu 340 345 350	1056
GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His 355 360 365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe 370 375 380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu 385 390 395 400	1200
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu	1248

	405	410	415	
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val	420	425	430	1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala	435	440	445	1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn	450	455	460	1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr	465	470	475	1440
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG. Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg	485	490	495	1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr	500	505	510	1536
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu	515	520	525	1584
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr	530	535	540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys	545	550	555	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His	565	570	575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe	580	585	590	1776
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala	595	600	605	1824
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys	610	615	620	1872
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val	625	630	635	1920
				640

CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA 1968
 Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:

 - (A) LENGTH: 1998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

ii) MOLECULE TYPE: cDNA

- ix) FEATURE:

 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..1995

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

```

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG      48
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
   1           5           10          15

```

CGC GGC AGC CAT ATG GGT TCT GTT GTT ATT GTT GGT AGA ATT ATT TTA
 Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
 20 25 30

TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA 144
 Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu
 35 40 45

CTT GGT TGC ATC AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC 192
 Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val
 50 55 60

GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG
 Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala
 65 70 75 80

ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA
 Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser
 85 90 95

AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT
Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn
100 105 110

GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC 384
 Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Glv Ala Arg Ser

	115	120	125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	130	135	140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	145	150	155	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly	165	170	175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala	180	185	190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu	195	200	205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser	210	215	220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro	225	230	235	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln	245	250	255	768
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly	260	265	270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg	275	280	285	864
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr	290	295	300	912
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Ala Tyr Asp	305	310	315	960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu	325	330	335	1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu	340	345	350	1056

GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His 355	360	365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe 370	375	380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu 385	390	395	400
ATT TTC TGT CAT TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu 405	410	415	1200
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val 420	425	430	1248
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala 435	440	445	1296
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn 450	455	460	1344
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr 465	470	475	1392
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg 485	490	495	1440
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr 500	505	510	1488
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515	520	525	1536
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530	535	540	1584
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545	550	555	1632
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565	570	575	1680
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe			1728
			1776

580	585	590	
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala			1824
595	600	605	
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys			1872
610	615	620	
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val			1920
625	630	635	640
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala			1968
645	650	655	
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT Cys Met Ser Ala Asp Leu Glu Val Val			1998
660	665		

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro			48
1	5	10	15
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu			96
20	25	30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			144
35	40	45	
CTT GGT TGC AAG AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val			192
50	55	60	

GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln 245 250 255	768
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly 260 265 270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg 275 280 285	864
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Gly Ala Pro Val Thr Tyr Ser Thr	912

290	295	300	
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp 305 310 315 320			960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu 325 330 335			1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu 340 345 350			1056
GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His 355 360 365			1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe 370 375 380			1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu 385 390 395 400			1200
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu 405 410 415			1248
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val 420 425 430			1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala 435 440 445			1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn 450 455 460			1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr 465 470 475 480			1440
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg 485 490 495			1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr 500 505 510			1536
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515 520 525			1584

TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530 535 540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545 550 555 560	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565 570 575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe 580 585 590	1776
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala 595 600 605	1824
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys 610 615 620	1872
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val 625 630 635 640	1920
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala 645 650 655	1968
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT Cys Met Ser Ala Asp Leu Glu Val Val 660 665	1998

(2) INFORMATION FOR SEQ ID NO:106:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1998 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15	48
---	----

CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu 35 40 45	144
CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val 50 55 60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA	768

Thr	Gly	Ser	Gly	Lys	Ser	Thr	Lys	Val	Pro	Ala	Ala	Tyr	Ala	Ala	Gln		
				245				250					255				
GGG	TAC	AAG	GTG	CTC	GTC	CTC	AAT	CCG	TCC	GCC	GCT	ACC	TTA	GGG		816	
Gly	Tyr	Lys	Val	Leu	Val	Leu	Asn	Pro	Ser	Val	Ala	Ala	Thr	Leu	Gly		
		260					265						270				
TTT	GGG	GCG	TAT	ATG	TCT	AAG	GCA	CAC	GGT	ATT	GAC	CCC	AAC	ATC	AGA		864
Phe	Gly	Ala	Tyr	Met	Ser	Lys	Ala	His	Gly	Ile	Asp	Pro	Asn	Ile	Arg		
		275					280						285				
ACT	GGG	GTA	AGG	ACC	ATT	ACC	ACA	GGC	GCC	CCC	GTC	ACA	TAC	TCT	ACC		912
Thr	Gly	Val	Arg	Thr	Ile	Thr	Thr	Gly	Ala	Pro	Val	Thr	Tyr	Ser	Thr		
		290					295					300					
TAT	GGC	AAG	TTT	CTT	GCC	GAT	GGT	GGT	TGC	TCT	GGG	GGC	GCT	TAT	GAC		960
Tyr	Gly	Lys	Phe	Leu	Ala	Asp	Gly	Gly	Cys	Ser	Gly	Gly	Ala	Tyr	Asp		
		305				310					315			320			
ATC	ATA	ATA	TGT	GAT	GAG	TGC	CAT	TCA	ACT	GAC	TCG	ACT	ACA	ATC	TTG		1008
Ile	Ile	Ile	Cys	Asp	Glu	Cys	His	Ser	Thr	Asp	Ser	Thr	Thr	Ile	Leu		
			325					330						335			
GGC	ATC	GGC	ACA	GTC	CTG	GAC	CAA	GCG	GAG	ACG	GCT	GGA	GCG	CGG	CTT		1056
Gly	Ile	Gly	Thr	Val	Leu	Asp	Gln	Ala	Glu	Thr	Ala	Gly	Ala	Arg	Leu		
			340				345						350				
GTC	GTG	CTC	GCC	ACC	GCT	ACG	CCT	CCG	GGA	TCG	GTC	ACC	GTG	CCA	CAC		1104
Val	Val	Leu	Ala	Thr	Ala	Thr	Pro	Pro	Gly	Ser	Val	Thr	Val	Pro	His		
		355				360						365					
CCA	AAC	ATC	GAG	GAG	GTG	GCC	CTG	TCT	AAT	ACT	GGA	GAG	ATC	CCC	TTC		1152
Pro	Asn	Ile	Glu	Glu	Val	Ala	Leu	Ser	Asn	Thr	Gly	Glu	Ile	Pro	Phe		
		370				375						380					
TAT	GGC	AAA	GCC	ATC	CCC	ATT	GAA	GCC	ATC	AGG	GGG	GGA	AGG	CAT	CTC		1200
Tyr	Gly	Lys	Ala	Ile	Pro	Ile	Glu	Ala	Ile	Arg	Gly	Gly	Arg	His	Leu		
		385				390					395			400			
ATT	TTC	TGT	CAT	TCC	AAG	AAG	AAG	TGC	GAC	GAG	CTC	GCC	GCA	AAG	CTG		1248
Ile	Phe	Cys	His	Ser	Lys	Lys	Cys	Asp	Glu	Leu	Ala	Ala	Lys	Leu			
			405					410						415			
TCA	GGC	CTC	GGA	ATC	AAC	GCT	GTG	GCG	TAT	TAC	CGG	GGG	CTC	GAT	GTG		1296
Ser	Gly	Leu	Gly	Ile	Asn	Ala	Val	Ala	Tyr	Tyr	Arg	Gly	Leu	Asp	Val		
			420				425						430				
TCC	GTC	ATA	CCA	ACT	ATC	GGA	GAC	GTC	GTT	GTC	GTG	GCA	ACA	GAC	GCT		1344
Ser	Val	Ile	Pro	Thr	Ile	Gly	Asp	Val	Val	Val	Val	Ala	Thr	Asp	Ala		
		435				440						445					
CTG	ATG	ACG	GGC	TAT	ACG	GGC	GAC	TTT	GAC	TCA	GTG	ATC	GAC	TGT	AAC		1392
Leu	Met	Thr	Gly	Tyr	Thr	Gly	Asp	Phe	Asp	Ser	Val	Ile	Asp	Cys	Asn		
		450				455						460					
ACA	TGT	GTC	ACC	CAG	ACA	GTC	GAC	TTC	AGC	TTG	GAT	CCC	ACC	TTC	ACC		1440
Thr	Cys	Val	Thr	Gln	Thr	Val	Asp	Phe	Ser	Leu	Asp	Pro	Thr	Phe	Thr		
		465				470					475			480			

ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg 485 490 495	1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr 500 505 510	1536
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515 520 525	1584
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530 535 540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545 550 555 560	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565 570 575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe 580 585 590	1776
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala 595 600 605	1824
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys 610 615 620	1872
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val 625 630 635 640	1920
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala 645 650 655	1968
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT Cys Met Ser Ala Asp Leu Glu Val Val 660 665	1998

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1998 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1997

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	48
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA. Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	96
20 25 30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu	144
35 40 45	
CTT GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val	192
50 55 60	
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala	240
65 70 75 80	
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser	288
85 90 95	
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn	336
100 105 110	
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser	384
115 120 125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg	432
130 135 140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser	480
145 150 155 160	
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly	528
165 170 175	

CCA CTG CTC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln 245 250 255	768
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly 260 265 270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg 275 280 285	864
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr 290 295 300	912
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp 305 310 315 320	960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu 325 330 335	1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu 340 345 350	1056
GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His 355 360 365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe 370 375 380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu 385 390 395 400	1200
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu	1248

	405	410	415	
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val	420	425	430	1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala	435	440	445	1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn	450	455	460	1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr	465	470	475	1440
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg	485	490	495	1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr	500	505	510	1536
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu	515	520	525	1584
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr	530	535	540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys	545	550	555	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His	565	570	575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe	580	585	590	1776
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala	595	600	605	1824
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys	610	615	620	1872
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val	625	630	635	1920
			640	

CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA 1968
 Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala
 645 650 655

TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT 1998
 Cys Met Ser Ala Asp Leu Glu Val Val
 660 665

(2) INFORMATION FOR SEQ ID NO:108:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1998 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG 48
 Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro
 1 5 10 15

CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA 96
 Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu
 20 25 30

TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA 144
 Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu
 35 40 45

CTT GGT TGC ATC AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC 192
 Leu Gly Cys Ile Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val
 50 55 60

GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG 240
 Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala
 65 70 75 80

ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA 288
 Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser
 85 90 95

AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT 336
 Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn
 100 105 110

GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC 384

Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser			
115	120	125	
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA			432
Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg			
130	135	140	
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC			480
His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser			
145	150	155	160
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT			528
Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly			
165	170	175	
CCA CTG CTC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC			576
Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala			
180	185	190	
GTA TGC ACC CCG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG			624
Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu			
195	200	205	
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC			672
Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser			
210	215	220	
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC			720
Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro			
225	230	235	240
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA			768
Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln			
245	250	255	
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG			816
Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly			
260	265	270	
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA			864
Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg			
275	280	285	
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC			912
Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr			
290	295	300	
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC			960
Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp			
305	310	315	320
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG			1008
Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu			
325	330	335	
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT			1056
Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu			
340	345	350	

GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His 355	360	365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe 370	375	380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu 385	390	395	400
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu 405	410	415	1248
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val 420	425	430	1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala 435	440	445	1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn 450	455	460	1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr 465	470	475	480
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg 485	490	495	1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr 500	505	510	1536
CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515	520	525	1584
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530	535	540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545	550	555	560
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565	570	575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC			1776

Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe			
580	585	590	
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC			1824
Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala			
595	600	605	
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA			1872
Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys			
610	615	620	
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC			1920
Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val			
625	630	635	640
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA			1968
Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala			
645	650	655	
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT			1998
Cys Met Ser Ala Asp Leu Glu Val Val			
660	665		

(2) INFORMATION FOR SEQ ID NO:109:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1998 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1997

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..1995

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG			48
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro			
1	5	10	15
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA			96
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu			
20	25	30	
TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA			144
Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu			
35	40	45	

CTT GGT TGC AAG AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC Leu Gly Cys Lys Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val 50 55 60	192
GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG Glu Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala 65 70 75 80	240
ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA Thr Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser 85 90 95	288
AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn 100 105 110	336
GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC Val Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser 115 120 125	384
TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg 130 135 140	432
CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC His Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser 145 150 155 160	480
CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly 165 170 175	528
CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CCG GCT GCC Pro Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala 180 185 190	576
GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu 195 200 205	624
TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC Ser Met Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser 210 215 220	672
CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC Pro Pro Ala Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro 225 230 235 240	720
ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln 245 250 255	768
GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly 260 265 270	816
TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA Phe Gly Ala Tyr Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg	864

	275	280	285	
ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC Thr Gly Val Arg Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr	290	295	300	912
TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp	305	310	315	960
ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG Ile Ile Ile Cys Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu	325	330	335	1008
GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT Gly Ile Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu	340	345	350	1056
GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His	355	360	365	1104
CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC Pro Asn Ile Glu Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe	370	375	380	1152
TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu	385	390	395	400
ATT TTC TGT CAT TCC AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG Ile Phe Cys His Ser Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu	405	410	415	1248
TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val	420	425	430	1296
TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT Ser Val Ile Pro Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala	435	440	445	1344
CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn	450	455	460	1392
ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC Thr Cys Val Thr Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr	465	470	475	480
ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG Ile Glu Thr Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg	485	490	495	1488
CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT Arg Gly Arg Thr Gly Arg Gly Arg Gly Ile Tyr Arg Phe Val Thr	500	505	510	1536

CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG Pro Gly Glu Arg Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu 515 520 525	1584
TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr 530 535 540	1632
TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys 545 550 555 560	1680
CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT Gln Asp His Leu Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His 565 570 575	1728
ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC Ile Asp Ala His Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe 580 585 590	1776
CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala 595 600 605	1824
CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA Pro Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys 610 615 620	1872
CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC Pro Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val 625 630 635 640	1920
CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA Gln Asn Glu Val Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala 645 650 655	1968
TGC ATG TCG GCT GAC CTG GAG GTC GTC ACT Cys Met Ser Ala Asp Leu Glu Val Val 660 665	1998

(2) INFORMATION FOR SEQ ID NO:110:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2016 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..2013

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro	48
1 5 10 15	
CGC GGC AGC CAT ATG GCT TAC TCT CTG ACT ACG GGT TCT GTT GTT ATT Arg Gly Ser His Met Ala Tyr Ser Leu Thr Thr Gly Ser Val Val Ile	96
20 25 30	
GTT GGT AGA ATT ATT TTA TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC Val Gly Arg Ile Ile Leu Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser	144
35 40 45	
CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly	192
50 55 60	
CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr Ala	240
65 70 75 80	
ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr Val	288
85 90 95	
TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC Tyr His Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile	336
100 105 110	
ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln Ala	384
115 120 125	
CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp	432
130 135 140	
CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg	480
145 150 155 160	
GAC GAC AGT AGG GGG AGC CTG CTC TCC CCC AGG CCT GTC TCC TAC TTG Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu	528
165 170 175	
AAG GGC TCT TCG GGT GGT CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala Val	576
180 185 190	
GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG GGG GTT GCG AAG GCG GTG Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val	624
195 200 205	
GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC Asp Phe Val Pro Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro Val	672
210 215 220	

TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG Phe Thr Asp Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val 225 230 235 240	720
GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro 245 250 255	768
GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser 260 265 270	816
GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly 275 280 285	864
ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ala 290 295 300	912
CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys 305 310 315 320	960
TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT Ser Gly Gly Ala Tyr Asp Ile Ile Cys Asp Glu Cys His Ser Thr 325 330 335	1008
GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu 340 345 350	1056
ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly 355 360 365	1104
TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Asn 370 375 380	1152
ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile 385 390 395 400	1200
AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT TCC AAG AAG AAG TGC GAC Arg Gly Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp 405 410 415	1248
GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr 420 425 430	1296
TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ile Gly Asp Val Val 435 440 445	1344
GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC	1392

Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp 450 455 460		
TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser 465 470 475 480		1440
TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Val Pro Gln Asp Ala 485 490 495		1488
GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC Val Ser Arg Ser Gln Arg Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly 500 505 510		1536
ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg Pro Ser Gly Met Phe Asp 515 520 525		1584
TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu 530 535 540		1632
CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG CGG GCC TAC CTG AAC ACA Leu Thr Pro Ala Glu Thr Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr 545 550 555 560		1680
CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Ser Val 565 570 575		1728
TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys 580 585 590		1776
CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val 595 600 605		1824
TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys 610 615 620		1872
TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu 625 630 635 640		1920
TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA Tyr Arg Leu Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile 645 650 655		1968
ACC AAA TAC ATC ATG GCA TGC ATG TCG GCT GAC CTG GAG GTC GTC Thr Lys Tyr Ile Met Ala Cys Met Ser Ala Asp Leu Glu Val Val 660 665 670		2013
ACT		2016

(2) INFORMATION FOR SEQ ID NO:111:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2016 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2013

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG	48
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	
1 5 10 15	
CGC GGC AGC CAT ATG GCT TAC TCT CTG ACT ACG GGT TCT GTT GTT ATT	96
Arg Gly Ser His Met Ala Tyr Ser Leu Thr Thr Gly Ser Val Val Ile	
20 25 30	
GTT GGT AGA ATT ATT TTA TCT GGT AGT GGT AGT ATC ACG GCC TAC TCC	144
Val Gly Arg Ile Ile Leu Ser Gly Ser Gly Ser Ile Thr Ala Tyr Ser	
35 40 45	
CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC ATC ACT AGC CTT ACA GGC	192
Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile Ile Thr Ser Leu Thr Gly	
50 55 60	
CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT CAG GTG GTT TCC ACC GCA	240
Arg Asp Lys Asn Gln Val Glu Gly Glu Val Gln Val Val Ser Thr Ala	
65 70 75 80	
ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC GGC GTG TGT TGG ACC GTT	288
Thr Gln Ser Phe Leu Ala Thr Cys Val Asn Gly Val Cys Trp Thr Val	
85 90 95	
TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC GGC CCA AAG GGG CCA ATC	336
Tyr His Ala Gly Ser Lys Thr Leu Ala Gly Pro Lys Gly Pro Ile	
100 105 110	
ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC CTC GTC GGC TGG CAG GCG	384
Thr Gln Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Gln Ala	
115 120 125	
CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC ACC TGT GGC AGC TCA GAC	432
Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp	
130 135 140	
CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC ATT CCG GTG CGC CGG CGG	480
Leu Tyr Leu Val Thr Arg His Ala Asp Val Ile Pro Val Arg Arg Arg	
145 150 155 160	

Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro Val Ser Tyr Leu			528
165	170	175	
AAG GGC TCT GCT GGT CCA CTG CTC TGC CCT TCG GGG CAC GCT GTG			576
Lys Gly Ser Ala Gly Gly Pro Leu Leu Cys Pro Ser Gly His Ala Val			
180	185	190	
Gly Ile Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val			624
195	200	205	
GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT ACT ATG CGG TCT CCG GTC			672
Asp Phe Val Pro Val Glu Ser Met Glu Thr Thr Met Arg Ser Pro Val			
210	215	220	
TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA CCG CAG TCA TTT CAA GTG			720
Phe Thr Asp Asn Ser Ser Pro Pro Ala Val Pro Gln Ser Phe Gln Val			
225	230	235	240
GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC AAG AGT ACT AAA GTG CCG			768
Ala His Leu His Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro			
245	250	255	
GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG CTC GTC CTC AAT CCG TCC			816
Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser			
260	265	270	
GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT ATG TCT AAG GCA CAC GGT			864
Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly			
275	280	285	
ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG ACC ATT ACC ACA GGC GCC			912
Ile Asp Pro Asn Ile Arg Thr Gly Val Arg Thr Ile Thr Thr Gly Ala			
290	295	300	
CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT CTT GCC GAT GGT GGT TGC			960
Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys			
305	310	315	320
TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT GAT GAG TGC CAT TCA ACT			1008
Ser Gly Gly Ala Tyr Asp Ile Ile Cys Asp Glu Cys His Ser Thr			
325	330	335	
GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA GTC CTG GAC CAA GCG GAG			1056
Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr Val Leu Asp Gln Ala Glu			
340	345	350	
ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC ACC GCT ACG CCT CCG GGA			1104
Thr Ala Gly Ala Arg Leu Val Val Leu Ala Thr Pro Pro Gly			
355	360	365	
TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG GAG GTG GCC CTG TCT AAT			1152
Ser Val Thr Val Pro His Pro Asn Ile Glu Glu Val Ala Leu Ser Asn			
370	375	380	
ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC ATC CCC ATT GAA GCC ATC			1200

Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala Ile Pro Ile Glu Ala Ile			
385	390	395	400
AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT TCC AAG AAG AAG TGC GAC			1248
Arg Gly Arg His Leu Ile Phe Cys His Ser Lys Lys Lys Cys Asp			
405	410	415	
GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA ATC AAC GCT GTG GCG TAT			1296
Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly Ile Asn Ala Val Ala Tyr			
420	425	430	
TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA ACT ATC GGA GAC GTC GTT			1344
Tyr Arg Gly Leu Asp Val Ser Val Ile Pro Thr Ile Gly Asp Val Val			
435	440	445	
GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC TAT ACG GGC GAC TTT GAC			1392
Val Val Ala Thr Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp			
450	455	460	
TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC CAG ACA GTC GAC TTC AGC			1440
Ser Val Ile Asp Cys Asn Thr Cys Val Thr Gln Thr Val Asp Phe Ser			
465	470	475	480
TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG ACC GTG CCT CAA GAC GCA			1488
Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr Val Pro Gln Asp Ala			
485	490	495	
GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT GGC AGG GGT AGG AGA GGC			1536
Val Ser Arg Ser Gln Arg Arg Gly Arg Thr Gly Arg Gly Arg Arg Gly			
500	505	510	
ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG CCC TCG GGC ATG TTC GAT			1584
Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg Pro Ser Gly Met Phe Asp			
515	520	525	
TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG GGC TGT GCT TGG TAC GAG			1632
Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Cys Ala Trp Tyr Glu			
530	535	540	
CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG CCG GCC TAC CTG AAC ACA			1680
Leu Thr Pro Ala Glu Thr Ser Val Arg Leu Arg Ala Tyr Leu Asn Thr			
545	550	555	560
CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG GAG TTC TGG GAG AGT GTC			1728
Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe Trp Glu Ser Val			
565	570	575	
TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC TTC TTG TCC CAG ACC AAG			1776
Phe Thr Gly Leu Thr His Ile Asp Ala His Phe Leu Ser Gln Thr Lys			
580	585	590	
CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA GCA TAC CAA GCC ACG GTG			1824
Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val			
595	600	605	
TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA TGG GAT CAA ATG TGG AAG			1872
Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp Gln Met Trp Lys			
610	615	620	

TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC GGG CCA ACA CCC TTG CTG Cys Leu Ile Arg Leu Lys Pro Thr Leu His Gly Pro Thr Pro Leu Leu 625 630 635 640	1920
TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC ACC CTC ACC CAC CCC ATA Tyr Arg Leu Gly Ala Val Gln Asn Glu Val Thr Leu Thr His Pro Ile 645 650 655	1968
ACC AAA TAC ATC ATG GCA TGC ATG TCG GCT GAC CTG GAG GTC GTC Thr Lys Tyr Ile Met Ala Cys Met Ser Ala Asp Leu Glu Val Val 660 665 670	2013
ACT	2016

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 648 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..648

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro 1 5 10 15	48
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu 20 25 30	96
TCT CCT GCT GGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT Ser Pro Ala Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu 35 40 45	144
GGT TGC ATC ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG Gly Cys Ile Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu 50 55 60	192
GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC Gly Glu Val Gln Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr 65 70 75 80	240
TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys 85 90 95	288

ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG	336
Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val	
100 105 110	
GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG	384
Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu	
115 120 125	
ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT	432
Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His	
130 135 140	
GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG	480
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu	
145 150 155 160	
CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA	528
Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro	
165 170 175	
CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA	576
Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val	
180 185 190	
TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC	624
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser	
195 200 205	
ATG GAA ACT ACT ATG CGG TCT TGA	648
Met Glu Thr Thr Met Arg Ser *	
210 215	

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 648 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..640

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113

ATG GGC AGC AGC CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG	48
Met Gly Ser Ser His His His His His Ser Ser Gly Leu Val Pro	
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT GTT ATT GGT AGA ATT ATT TTA	96

Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu				
20	25	30		
TCT CCT GCT GGT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT				144
Ser Pro Ala Gly Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu				
35	40	45		
Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu				192
50	55	60		
GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC				240
Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr				
65	70	75	80	
TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG				288
Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys				
85	90	95		
ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG				336
Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val				
100	105	110		
GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG				384
Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu				
115	120	125		
ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT				432
Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His				
130	135	140		
GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG				480
Ala Asp Val Ile Pro Val Arg Arg Arg Gly Asp Ser Arg Gly Ser Leu				
145	150	155	160	
CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA				528
Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro				
165	170	175		
CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA				576
Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val				
180	185	190		
TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC				624
Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser				
195	200	205		
ATG GAA ACT ACT ATG C GGTCTTGA				648
Met Glu Thr Thr Met				
210				

(2) INFORMATION FOR SEQ ID NO:114:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 498 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..498

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

ATG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG	48
Met Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu	
1 5 10 15	
GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC	96
Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val	
20 25 30	
AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA	144
Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu	
35 40 45	
GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG	192
Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln	
50 55 60	
GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA	240
Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro	
65 70 75 80	
TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC	288
Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp	
85 90 95	
GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC	336
Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser	
100 105 110	
CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA CTG CTC	384
Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu	
115 120 125	
TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC	432
Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr	
130 135 140	
CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA	480
Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu	
145 150 155 160	
ACT ACT ATG CGG TCT TGA	498
Thr Thr Met Arg Ser *	
165	

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 648 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..648

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

ATG GGC AGC AGC CAT CAT CAT CAT CAT CAC AGC AGC GGC CTG GTG CCG-	48
Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro	
1 5 10 15	
CGC GGC AGC CAT ATG GGT TCT GTT ATT GTT GGT AGA ATT ATT TTA	96
Arg Gly Ser His Met Gly Ser Val Val Ile Val Gly Arg Ile Ile Leu	
20 25 30	
TCT GGT GGT TCT ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT	144
Ser Gly Gly Ser Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu	
35 40 45	
GGT TGC AAG ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG	192
Gly Cys Lys Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu	
50 55 60	
GGA GAG GTT CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC	240
Gly Glu Val Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr	
65 70 75 80	
TGC GTC AAC GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG	288
Cys Val Asn Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys	
85 90 95	
ACC TTA GCC GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG	336
Thr Leu Ala Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val	
100 105 110	
GAC CAG GAC CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG	384
Asp Gln Asp Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu	
115 120 125	
ACA CCA TGC ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT	432
Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His	
130 135 140	
GCT GAC GTC ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG	480
Ala Asp Val Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu	
145 150 155 160	

CTC TCC CCC AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA Leu Ser Pro Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro 165	170	175	528
CTG CTC TGC CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA Leu Leu Cys Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val 180	185	190	576
TGC ACC CGG GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser 195	200	205	624
ATG GAA ACT ACT ATG CGG TCT TGA Met Glu Thr Thr Met Arg Ser *	210	215	648

(2) INFORMATION FOR SEQ ID NO:116:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2007 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..2004

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

ATG CAT ATG CAT CAT CAC CAT CAT CTG GTG CCG CGC GGC AGC GCG Met His Met His His His His His His Leu Val Pro Arg Gly Ser Ala 1	5	10	15	48
CCC ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT GGT TGC AAG Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Lys 20	25	30		96
ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val 35	40	45		144
CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn 50	55	60		192
GCG GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala 65	70	75	80	240
GCG CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC				288

Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp				
85	90	95		
CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC				336
Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys				
100	105	110		
ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC				384
Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val				
115	120	125		
ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC CCC				432
Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro				
130	135	140		
AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA CTG CTC TGC				480
Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys				
145	150	155	160	
CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG				528
Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg				
165	170	175		
GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT				576
Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr				
180	185	190		
ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA				624
Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val				
195	200	205		
CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC				672
Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly				
210	215	220		
AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG				720
Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Gln Gly Tyr Lys Val				
225	230	235	240	
CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT				768
Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr				
245	250	255		
ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG				816
Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg				
260	265	270		
ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT				864
Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe				
275	280	285		
CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT				912
Leu Ala Asp Gly Gly Cys Ser Gly Ala Tyr Asp Ile Ile Ile Cys				
290	295	300		
GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA				960
Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr				
305	310	315	320	

GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 325	330	335	1008
ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 340	345	350	1056
GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 355	360	365	1104
ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 370	375	380	1152
TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 385	390	395	400
ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 405	410	415	1248
ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 420	425	430	1296
TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 435	440	445	1344
CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr 450	455	460	1392
ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr 465	470	475	480
GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg 485	490	495	1488
CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala 500	505	510	1536
GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu 515	520	525	1584
CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu 530	535	540	1632
GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC			1680

Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His				
545	550	555	560	
TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA				1728
Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val				
565	570	575		
GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA				1776
Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser				
580	585	590		
TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC				1824
Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His				
595	600	605		
GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC				1872
Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val				
610	615	620		
ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA TGC ATG TCG GCC				1920
Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala				
625	630	635	640	
GAC CTG GAG GTC GTT ACG TAG GAA TTC GAG CTC CGT CGA CAA GCT TGC				1968
Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys				
645	650	655		
GGC CGC ACT CGA GCA CCA CCA CCA CCA CCA CTG AGA TCC				2007
Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg				
660	665			

(2) INFORMATION FOR SEQ ID NO:117:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2007 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2004

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

ATG CAT ATG CAT CAT CAC CAT CAT CTG GTG CCG CGC GGC AGC GCG				48
Met His Met His His His His His Leu Val Pro Arg Gly Ser Ala				
1	5	10	15	
CCC ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC				96
Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile				

20	25	30	
AAG ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT Lys Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val 35	40	45	144
CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn 50	55	60	192
GCG GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala 65	70	75	240
GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp 85	90	95	288
CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA TGG Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys 100	105	110	336
ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val 115	120	125	384
ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC CCC Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro 130	135	140	432
AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA CTG CTC TGC Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys 145	150	155	480
CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg 165	170	175	528
GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 180	185	190	576
ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 195	200	205	624
CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 210	215	220	672
AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 225	230	235	720
CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 245	250	255	768

ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 260 265 270	816
ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe 275 280 285	864
CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 290 295 300	912
GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 305 310 315 320	960
GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 325 330 335	1008
ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 340 345 350	1056
GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 355 360 365	1104
ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 370 375 380	1152
TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 385 390 395 400	1200
ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 405 410 415	1248
ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 420 425 430	1296
TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 435 440 445	1344
CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr 450 455 460	1392
ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr 465 470 475 480	1440
GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg	1488

485	490	495	
CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala 500	505	510	1536
GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu 515	520	525	1584
CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu 530	535	540	1632
GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His 545	550	555	1680
TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val 565	570	575	1728
GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser 580	585	590	1776
TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His 595	600	605	1824
GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val 610	615	620	1872
ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA TGC ATG TCG GCC Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala 625	630	635	1920
GAC CTG GAG GTC GTT ACG TAG GAA TTC GAG CTC CGT CGA CAA GCT TGC Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys 645	650	655	1968
GGC CGC ACT CGA GCA CCA CCA CCA CCA CTG AGA TCC Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg 660	665		2007

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2007 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 1..2004

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

ATG CAT ATG CAT CAT CAC CAT CAT CTG GTG CCG CGC GGC AGC GCG Met His Met His His His His His His His Leu Val Pro Arg Gly Ser Ala	1	5	10	15	48
CCC ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile	20	25	30		96
ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val	35	40	45		144
CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn	50	55	60		192
GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala	65	70	75	80	240
GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp	85	90	95		288
CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys	100	105	110		336
ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val	115	120	125		384
ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC CCC Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro	130	135	140		432
AGG CCT GTC TCC TAC TTG AAG GGC TCT GCT GGT GGT CCA CTG CTC TGC Arg Pro Val Ser Tyr Leu Lys Gly Ser Ala Gly Gly Pro Leu Leu Cys	145	150	155	160	480
CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg	165	170	175		528
GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr	180	185	190		576
ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val	195	200	205		624

CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 210 215 220	672
AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 225 230 235 240	720
CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 245 250 255	768
ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 260 265 270	816
ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe 275 280 285	864
CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 290 295 300	912
GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 305 310 315 320	960
GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 325 330 335	1008
ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 340 345 350	1056
GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 355 360 365	1104
ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 370 375 380	1152
TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 385 390 395 400	1200
ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 405 410 415	1248
ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC Thr Ile Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 420 425 430	1296
TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC	1344

Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr			
435	440	445	
CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG			1392
Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr			
450	455	460	
ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT			1440
Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr			
465	470	475	480
GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG			1488
Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg			
485	490	495	
CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG			1536
Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala			
500	505	510	
GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG			1584
Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu			
515	520	525	
CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG			1632
Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu			
530	535	540	
GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC			1680
Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His			
545	550	555	560
TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA			1728
Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val			
565	570	575	
GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA			1776
Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser			
580	585	590	
TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC			1824
Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His			
595	600	605	
GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC			1872
Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val			
610	615	620	
ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA TGC ATG TCG GCC			1920
Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala			
625	630	635	640
GAC CTG GAG GTC GTT ACG TAG GAA TTC GAG CTC CGT CGA CAA GCT TGC			1968
Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys			
645	650	655	
GGC CGC ACT CGA GCA CCA CCA CCA CCA CCA CTG AGA TCC			2007
Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg			
660	665		

(2) INFORMATION FOR SEQ ID NO:119:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2007 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2004

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

ATG CAT ATG CAT CAT CAC CAT CAT CTG GTG CCG CGC GGC AGC GCG Met His Met His His His His His His Leu Val Pro Arg Gly Ser Ala	48
1 5 10 15	
CCC ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile	96
20 25 30	
ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val	144
35 40 45	
CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn	192
50 55 60	
GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala	240
65 70 75 80	
GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp	288
85 90 95	
CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys	336
100 105 110	
ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val	384
115 120 125	
ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC CCC Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro	432
130 135 140	
AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA CTG CTC TGC	480

Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys 145 150 155 160		
CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg 165 170 175		528
GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 180 185 190		576
ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 195 200 205		624
CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 210 215 220		672
AAG AGT ACT AAA GTG CCG GCT GCA TAT GCA GCC CAA GGG TAC AAG GTG Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Gln Gly Tyr Lys Val 225 230 235 240		720
CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 245 250 255		768
ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 260 265 270		816
ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe 275 280 285		864
CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 290 295 300		912
GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 305 310 315 320		960
GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala 325 330 335		1008
ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu 340 345 350		1056
GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala 355 360 365		1104
ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His 370 375 380		1152

TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly 385 390 395 400	1200
ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro 405 410 415	1248
ACT TCC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC Thr Ser Gly Asp Val Val Val Ala Thr Asp Ala Leu Met Thr Gly 420 425 430	1296
TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr 435 440 445	1344
CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr 450 455 460	1392
ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr 465 470 475 480	1440
GCG AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg 485 490 495	1488
CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala 500 505 510	1536
GCG TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu 515 520 525	1584
CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu 530 535 540	1632
GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His 545 550 555 560	1680
TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val 565 570 575	1728
GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser 580 585 590	1776
TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His 595 600 605	1824
GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC	1872

Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val			
610	615	620	
ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA TGC ATG TCG GCC			1920
Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala			
625	630	635	640
GAC CTG GAG GTC GTT ACG TAG GAA TTC GAG CTC CGT CGA CAA GCT TGC			1968
Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys			
645	650	655	
GGC CGC ACT CGA GCA CCA CCA CCA CCA CCA CTG AGA TCC			2007
Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg			
660	665		

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2007 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..2007

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

ATG CAT ATG CAT CAT CAC CAT CAT CTG GTG CCG CGC GGC AGC GCG			48
Met His Met His His His His His Leu Val Pro Arg Gly Ser Ala			
1	5	10	15
CCC ATC ACG GCC TAC TCC CAA CAG ACG CGG GGC CTA CTT GGT TGC ATC			96
Pro Ile Thr Ala Tyr Ser Gln Gln Thr Arg Gly Leu Leu Gly Cys Ile			
20	25	30	
ATC ACT AGC CTT ACA GGC CGG GAC AAG AAC CAG GTC GAG GGA GAG GTT			144
Ile Thr Ser Leu Thr Gly Arg Asp Lys Asn Gln Val Glu Gly Glu Val			
35	40	45	
CAG GTG GTT TCC ACC GCA ACA CAA TCC TTC CTG GCG ACC TGC GTC AAC			192
Gln Val Val Ser Thr Ala Thr Gln Ser Phe Leu Ala Thr Cys Val Asn			
50	55	60	
GGC GTG TGT TGG ACC GTT TAC CAT GGT GCT GGC TCA AAG ACC TTA GCC			240
Gly Val Cys Trp Thr Val Tyr His Gly Ala Gly Ser Lys Thr Leu Ala			
65	70	75	80
GGC CCA AAG GGG CCA ATC ACC CAG ATG TAC ACT AAT GTG GAC CAG GAC			288
Gly Pro Lys Gly Pro Ile Thr Gln Met Tyr Thr Asn Val Asp Gln Asp			
85	90	95	

CTC GTC GGC TGG CAG GCG CCC CCC GGG GCG CGT TCC TTG ACA CCA TGC Leu Val Gly Trp Gln Ala Pro Pro Gly Ala Arg Ser Leu Thr Pro Cys 100 105 110	336
ACC TGT GGC AGC TCA GAC CTT TAC TTG GTC ACG AGA CAT GCT GAC GTC Thr Cys Gly Ser Ser Asp Leu Tyr Leu Val Thr Arg His Ala Asp Val 115 120 125	384
ATT CCG GTG CGC CGG CGG GGC GAC AGT AGG GGG AGC CTG CTC TCC CCC Ile Pro Val Arg Arg Gly Asp Ser Arg Gly Ser Leu Leu Ser Pro 130 135 140	432
AGG CCT GTC TCC TAC TTG AAG GGC TCT TCG GGT GGT CCA CTG CTC TGC Arg Pro Val Ser Tyr Leu Lys Gly Ser Ser Gly Gly Pro Leu Leu Cys 145 150 155 160	480
CCT TCG GGG CAC GCT GTG GGC ATC TTC CGG GCT GCC GTA TGC ACC CGG Pro Ser Gly His Ala Val Gly Ile Phe Arg Ala Ala Val Cys Thr Arg 165 170 175	528
GGG GTT GCG AAG GCG GTG GAC TTT GTG CCC GTA GAG TCC ATG GAA ACT Gly Val Ala Lys Ala Val Asp Phe Val Pro Val Glu Ser Met Glu Thr 180 185 190	576
ACT ATG CGG TCT CCG GTC TTC ACG GAC AAC TCA TCC CCC CCG GCC GTA Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro Pro Ala Val 195 200 205	624
CCG CAG TCA TTT CAA GTG GCC CAC CTA CAC GCT CCC ACT GGC AGC GGC Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr Gly Ser Gly 210 215 220	672
AAG AGT ACT AAA GTG CCG GCT GCC TAC GCA GCC CAA GGG TAC AAG GTG Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly Tyr Lys Val 225 230 235 240	720
CTC GTC CTC AAT CCG TCC GTT GCC GCT ACC TTA GGG TTT GGG GCG TAT Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe Gly Ala Tyr 245 250 255	768
ATG TCT AAG GCA CAC GGT ATT GAC CCC AAC ATC AGA ACT GGG GTA AGG Met Ser Lys Ala His Gly Ile Asp Pro Asn Ile Arg Thr Gly Val Arg 260 265 270	816
ACC ATT ACC ACA GGC GCC CCC GTC ACA TAC TCT ACC TAT GGC AAG TTT Thr Ile Thr Thr Gly Ala Pro Val Thr Tyr Ser Thr Tyr Gly Lys Phe 275 280 285	864
CTT GCC GAT GGT GGT TGC TCT GGG GGC GCT TAT GAC ATC ATA ATA TGT Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp Ile Ile Ile Cys 290 295 300	912
GAT GAG TGC CAT TCA ACT GAC TCG ACT ACA ATC TTG GGC ATC GGC ACA Asp Glu Cys His Ser Thr Asp Ser Thr Thr Ile Leu Gly Ile Gly Thr 305 310 315 320	960
GTC CTG GAC CAA GCG GAG ACG GCT GGA GCG CGG CTT GTC GTG CTC GCC Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val Val Leu Ala	1008

	325	330	335	
ACC GCT ACG CCT CCG GGA TCG GTC ACC GTG CCA CAC CCA AAC ATC GAG Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro Asn Ile Glu	340	345	350	1056
GAG GTG GCC CTG TCT AAT ACT GGA GAG ATC CCC TTC TAT GGC AAA GCC Glu Val Ala Leu Ser Asn Thr Gly Glu Ile Pro Phe Tyr Gly Lys Ala	355	360	365	1104
ATC CCC ATT GAA GCC ATC AGG GGG GGA AGG CAT CTC ATT TTC TGT CAT Ile Pro Ile Glu Ala Ile Arg Gly Gly Arg His Leu Ile Phe Cys His	370	375	380	1152
TCC AAG AAG AAG TGC GAC GAG CTC GCC GCA AAG CTG TCA GGC CTC GGA Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Ser Gly Leu Gly	385	390	395	1200
ATC AAC GCT GTG GCG TAT TAC CGG GGG CTC GAT GTG TCC GTC ATA CCA Ile Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser Val Ile Pro	405	410	415	1248
ACT ATC GGA GAC GTC GTT GTC GTG GCA ACA GAC GCT CTG ATG ACG GGC Thr Ile Gly Asp Val Val Val Val Ala Thr Asp Ala Leu Met Thr Gly	420	425	430	1296
TAT ACG GGC GAC TTT GAC TCA GTG ATC GAC TGT AAC ACA TGT GTC ACC Tyr Thr Gly Asp Phe Asp Ser Val Ile Asp Cys Asn Thr Cys Val Thr	435	440	445	1344
CAG ACA GTC GAC TTC AGC TTG GAT CCC ACC TTC ACC ATT GAG ACG ACG Gln Thr Val Asp Phe Ser Leu Asp Pro Thr Phe Thr Ile Glu Thr Thr	450	455	460	1392
ACC GTG CCT CAA GAC GCA GTG TCG CGC TCG CAG CGG CGG GGT AGG ACT Thr Val Pro Gln Asp Ala Val Ser Arg Ser Gln Arg Arg Gly Arg Thr	465	470	475	1440
GGC AGG GGT AGG AGA GGC ATC TAC AGG TTT GTG ACT CCG GGA GAA CGG Gly Arg Gly Arg Arg Gly Ile Tyr Arg Phe Val Thr Pro Gly Glu Arg	485	490	495	1488
CCC TCG GGC ATG TTC GAT TCC TCG GTC CTG TGT GAG TGC TAT GAC GCG Pro Ser Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala	500	505	510	1536
GGC TGT GCT TGG TAC GAG CTC ACC CCC GCC GAG ACC TCG GTT AGG TTG Gly Cys Ala Trp Tyr Glu Leu Thr Pro Ala Glu Thr Ser Val Arg Leu	515	520	525	1584
CGG GCC TAC CTG AAC ACA CCA GGG TTG CCC GTT TGC CAG GAC CAC CTG Arg Ala Tyr Leu Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu	530	535	540	1632
GAG TTC TGG GAG AGT GTC TTC ACA GGC CTC ACC CAT ATA GAT GCA CAC Glu Phe Trp Glu Ser Val Phe Thr Gly Leu Thr His Ile Asp Ala His	545	550	555	1680
			560	

TTC TTG TCC CAG ACC AAG CAG GCA GGA GAC AAC TTC CCC TAC CTG GTA Phe Leu Ser Gln Thr Lys Gln Ala Gly Asp Asn Phe Pro Tyr Leu Val 565	570	575	1728	
GCA TAC CAA GCC ACG GTG TGC GCC AGG GCT CAG GCC CCA CCT CCA TCA Ala Tyr Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser 580	585	590	1776	
TGG GAT CAA ATG TGG AAG TGT CTC ATA CGG CTG AAA CCT ACG CTG CAC Trp Asp Gln Met Trp Lys Cys Leu Ile Arg Leu Lys Pro Thr Leu His 595	600	605	1824	
GGG CCA ACA CCC TTG CTG TAC AGG CTG GGA GCC GTC CAA AAT GAG GTC Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln Asn Glu Val 610	615	620	1872	
ACC CTC ACC CAC CCC ATA ACC AAA TAC ATC ATG GCA TGC ATG TCG GCC Thr Leu Thr His Pro Ile Thr Lys Tyr Ile Met Ala Cys Met Ser Ala 625	630	635	640	1920
GAC CTG GAG GTC GTT ACG TAG GAA TTC GAG CTC CGT CGA CAA GCT TGC Asp Leu Glu Val Val Thr * Glu Phe Glu Leu Arg Arg Gln Ala Cys 645	650	655	1968	
GGC CGC ACT CGA GCA CCA CCA CCA CCA CCA CTG AGA TCC Gly Arg Thr Arg Ala Pro Pro Pro Pro Leu Arg Ser 660	665		2007	

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

GCUCGCCCGG GGAUCCUCUA GGAAUACACG UUCGAU 36

(2) INFORMATION FOR SEQ ID NO:122:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: RNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

CUAGAGGAUC CCCGGGCGAG CCCUAUAGUG AGUCGU 36

(2) INFORMATION FOR SEQ ID NO:123:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

GCTCGCCCGG GGATCCTCTA G 21




Fig. 1






Fig. 2




Fig. 3





Fig. 5

A. Substrate Alone



B. Substrate + Enzyme




Figure 6





Figure 7



DECLARATION AND POWER OF
ATTORNEY FOR PROVISIONAL PATENT APPLICATION

Attorney's Docket No. JB0800

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SINGLE-CHAIN RECOMBINANT COMPLEXES OF HEPATITIS C VIRUS NS3 PROTEASE AND NS4A COFACTOR PEPTIDE

the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):	Priority Claimed		
(Number)	(Country)	(Day/Month/Year Filed)	Yes or No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

60/067,315	November 28, 1997
(Application Number)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status – patented, pending, abandoned)
--------------------------	---------------	---

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number.)

Carl W. Battle	Reg. No. 30731	John J. Maitner	Reg. No. 25636
Edwin P. Ching	Reg. No. 34090	Joseph T. Majka	Reg. No. 30570
Eric S. Dicker	Reg. No. 31699	Arthur Mann	Reg. No. 35598
Norman C. Dulak	Reg. No. 31608	Edward H. Mazer	Reg. No. 27573
Cynthia L. Foulke	Reg. No. 32364	Jaye P. McLaughlin	Reg. No. 41211
Robert A. Franks	Reg. No. 28605	Sheela Mohan-Peterson	Reg. No. 41201
James M. Gould	Reg. No. 33702	Richard B. Murphy	Reg. No. 35296
Richard J. Grochala	Reg. No. 31518	James R. Nelson	Reg. No. 27929
Thomas D. Hoffman	Reg. No. 28221	Immac J. Thampoe	Reg. No. 36322
Henry C. Jeanette	Reg. No. 30856	Paul A. Thompson	Reg. No. 35385
Susan Lee	Reg. No. 30653	Donald W. Wyatt	Reg. No. 40,876
Anita W. Magatti	Reg. No. 29825		

Send Correspondence to:	Direct Telephone Calls to:	
Jaye P. McLaughlin Schering-Plough Corporation Patent Department, K-6-1, 1990 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530	Name: Telephone No.: Facsimile No.:	Jaye P. McLaughlin (908) 298-5056 (908) 298-5388

FULL NAME OF 1ST OR SOLE INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Malcolm	Bruce	A.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Westfield	New Jersey	USA
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	515 Trinity Place	Westfield	New Jersey 07090 USA

FULL NAME OF 2ND JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Taremi	S. Shane	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Upper Montclair	New Jersey	Iran
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	12 Park Terrace	Upper Montclair	New Jersey 07043 USA

FULL NAME OF 3RD JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Weber	Patricia	C.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Yardley	Pennsylvania	USA
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	1970 Timber Lakes Drive	Yardley	Pennsylvania 19067 USA

FULL NAME OF 4TH JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Yao	Nanhua	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Edison	New Jersey	Peoples Republic of China
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	4 Timothy Court	Edison	New Jersey 08837 USA

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor	Signature of Second Inventor	Signature of Third Inventor
Date <u>11-18-98</u>	Date <u>11-18-98</u>	Date <u>11-18-98</u>

Bruce A. Malcolm

S. Shane Taremi

Patricia C. Weber

Signature of Fourth Inventor
Date

Nanhua Yao

Rev. 1/96 JHB